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“.. and yet it doesn’t matter if he’s all in bits. The whole is disorganized. But 
each individual fragment is in order, is a representative of a Higher Order. The 
Highest Order prevails even in the disintegration. The totality is present even 
in the broken pieces. More clearly present, perhaps, than in a completely 
coherent work. At least you aren’t lulled into a sense of false security by some 
merely human, merely fabricated order. You have to rely on your immediate 
perception of the ultimate order. So in a certain sense disintegration may have 
its advantages. But of course it’s dangerous, horribly dangerous.  
Suppose you couldn’t get back, out of the chaos..” 
 
Aldous Huxley, The Doors of Perception, 1954 
 
 
 
 
 
 
 
 
 
(I can’t get no) Satisfaction 
 
The Rolling Stones, 1965!
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Abstract 
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Autophagy is a lysosomal pathway deputed to the recycling of cellular components. 
Regulation of autophagy is essential for tissue homeostasis. The mTORC1 kinase 
tunes autophagy according to nutrient levels and environmental factors. Recently 
the laboratory in which I performed the experiments used for my thesis has 
demonstrated that autophagy, by controlling collagen secretion in chondrocytes, is 
necessary during bone growth. However, whether mTORC1 and autophagy play 
any role in the pathogenesis of skeletal disorders is still unknown. In this thesis 
work I show that an altered mTORC1 signaling impairs autophagy and 
consequently bone growth in lysosomal storage disorders (LSDs). I found that in 
LSD chondrocytes a proteasome-sensitive increase of mTORC1 signaling inhibits 
late steps of autophagy through the phosphorylation of the UV radiation 
resistance-associated gene (UVRAG) protein, a member of the Beclin1/Vps34 
complex. Reducing mTORC1 signaling or enhancing Beclin1/Vps34/UVRAG 
complex activity rescued autophagy flux in LSD chondrocytes. In vivo, 
normalization of mTORC1 signaling or pharmacological induction of Beclin1 
rescued collagen levels in cartilage and bone growth in two different LSD mouse 
models. Taken together, these data unveil a role for mTORC1 and autophagy in 
the pathogenesis of skeletal disorders and suggest their modulation as new therapy 
for the skeletal abnormalities observed in LSDs. 
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1. Skeletogenesis.  
The process by which bones are formed is called ossification. Ossification is an 
extremely complex, life-long process. Formation of the adult skeleton is achieved 
through two independent mechanisms: intramembranous and endochondral 
ossification[1]. In intramembranous bone formation, mesenchymal cells directly 
differentiate into osteoblasts. Some of the craniofacial bones are formed this way. 
Endochondral ossification (EO) is the process responsible for formation of the majority 
of bones in the vertebrate skeleton. EO starts from mesenchymal cells that condense at 
the position of future bone, through a complex process of chondrogenesis to form a 
highly controlled and precisely shaped cartilage template[2].  
The cartilage template grows through chondrocyte proliferation and differentiation to 
establish the cartilage growth plate that ultimately drives the longitudinal growth of the 
bone. This process eventually determines the adult height. Long bones such as femur 
and tibia are formed through this process. Finally, a process of growth and remodeling 
after birth (in a growth and maintenance phase) results in a skeleton which is well 
adapted to its function as an organ not only for support and protection of internal 
organs, but also for movement, blood cell formation and regulation of calcium 
homeostasis.  
1.1 Endochondral bone formation.  
Endochondral ossification is initiated by aggregation of mesenchymal cells, followed by 
cell differentiation into chondrocytes through the process of chondrogenesis (Figure 1).  
! 5!
 
Figure 1. Overview of endochondral ossification.  
During embryogenesis, mesenchymal cells start to aggregate and condense at the location of 
future bone. They then differentiate into chondrocyte in the center of these condensations 
through chondrogenesis. Chondrocytes proliferate and differentiate within these condensations 
leading to the formation of cartilage anlagen. At the periphery of the condensations, cells 
flatten, elongate and form the perichondrium. These chondrocytes also keep proliferating to 
expand the cartilage template. Eventually, cells at the center of this template terminally 
differentiate into hypertrophic cells. Perichondral cells adjacent to hypertrophic chondrocyte 
become osteoblasts, forming a bone collar. Hypertrophic chondrocyte direct mineralization of 
the surrounding cartilage matrix, attract blood vessel invasion, and then undergo apoptosis. 
Osteoblasts form early trabecular bone adjacent to the hypertrophic chondrocytes, forming the 
primary spongiosa. Epiphyseal growth plates form at both ends of the long bone with unique 
organization of the chondrocytes. At the end of the bone, the secondary ossification center 
forms through cycles of chondrocyte hypertrophy, vascular invasion and osteoblast activity. 
(Created according to [1-3]) 
 
During embryogenesis, mesenchymal cells start to aggregate and condense at the 
location of future bone. They then differentiate into chondrocyte in the center of these 
condensations through chondrogenesis. Chondrocytes proliferate and differentiate 
within these condensations leading to the formation of cartilage anlagen. At the 
periphery of the condensations, cells flatten, elongate and form the perichondrium. 
These chondrocytes also keep proliferating to expand the cartilage template. Eventually, 
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cells at the center of this template terminally differentiate into hypertrophic cells. 
Perichondral cells adjacent to hypertrophic chondrocyte become osteoblasts, forming a 
bone collar. Hypertrophic chondrocyte direct mineralization of the surrounding cartilage 
matrix, attract blood vessel invasion, and then undergo apoptosis. Osteoblasts form 
early trabecular bone adjacent to the hypertrophic chondrocytes, forming the primary 
spongiosa. Epiphyseal growth plates form at both ends of the long bone with unique 
organization of the chondrocytes. At the end of the bone, the secondary ossification 
center forms through cycles of chondrocyte hypertrophy, vascular invasion and 
osteoblast activity[1].  
Chondrogenesis is a highly complex process leading to the formation of a cartilage 
template. Early condensations can be found in the human fetus at 6.5 weeks of gestation 
and at embryonic (E) 10.5 days (E10.5) of mouse development. At this time point in 
development, the shape, number and position of future skeletal elements are decided[3]. 
Members of the Sox family of transcription factors (Sox9, Sox5 and Sox6) are required 
for this early differentiation[2]. Cells in the condensations differentiate to chondrocytes 
and deposit an extracellular matrix specific for cartilage, consisting of molecules such 
as collagens II, IX, and XI and proteoglycans (e.g. aggrecan). At the border of the 
condensations, chondrocytes differentiate to flattened elongated cells to form the 
perichondrium[1]. All these events contribute to the establishment of cartilage anlagen 
for the future bone elements. 
1.2  Epiphyseal growth plate.  
Once mesenchymal cells commit to the chondrogenic lineage, the subsequent events of 
EO occur through the epiphyseal growth plate. Longitudinal bone growth dictates the 
final height of human bodies and is dependent on the activity of the growth plates[4]. 
The growth plate is a unique structure where specific chondrocyte populations are 
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organized in distinct zones (e.g. zones of resting, proliferating, and hypertrophic 
chondrocytes) based on their morphology, cellular activities and gene expression 
patterns (Figure 2). Within these zones, the chondrocytes are organized in 
distinguishable columnar arrays and express different matrix proteins. 
 
 
Figure 2. Local regulators of growth plate and life cycle of chondrocyte.  
Longitudinal growth of the cartilage growth plate is under control of many secreted factors and 
endogenous regulators such as transcription factors. Each stage of chondrocyte is characterized 
by expression of specific molecular markers and matrix proteins (in red): the aggregates of 
mesenchymal cells express BMPs and Sox family proteins; resting cells express Sox proteins, 
PTH/PTHrP, FGFR2 and collagen II; proliferative chondrocytes express FGFR3, cell cycle 
proteins such as Cyclins D1 and A, and collagen II and aggrecan; prehypertrophic cells are 
under control of the transcription factor RUNX2, and express Ihh and FGFs; hypertrophic cells 
express collagen X, MMP13 and ALP in bone matrix. (Created according to [1-3]) 
 
The resting chondrocytes are small round cells in a relatively quiescent state and located 
furthest away from the primary ossification center. It is believed that some of these cells 
have stem-like properties, and can give rise to the neighboring proliferative zone. 
Within this zone of the growth plate, flattened proliferating chondrocytes are organized 
in a columnar array, and proliferation of chondrocytes occurs in a unidirectional 
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manner, resulting in longitudinal growth of the bone. Both resting and proliferating 
chondrocytes express extracellular matrix (ECM) molecules, such as collagen II and 
aggrecan[1]. Throughout chondrogenesis, the balance of signaling by growth factors 
such as bone morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs) 
determines the rate of proliferation[5].  
1.3 Chondrocyte hypertrophy and extracellular matrix production.  
Chondrocytes in the center of the cartilage mould then stop proliferating, start to 
differentiate into prehypertrophic cells, and eventually enlarge to terminally 
differentiated hypertrophic chondrocytes under the control of several cell cycle genes 
and different transcription factors[1], [2]. The transcription factor RUNX2 (runt related 
transcript factor 2) is required for this terminal chondrocyte differentiation[4].  
Hypertrophic chondrocytes are the principle regulators of the subsequent events of bone 
growth[2]. They change their gene expression pattern to synthesize type X collagen, 
direct the mineralization of their extracellullar matrix, attract blood vessel invasion 
through the production of vascular endothelial growth factor (VEGF), activate 
osteoclasts to digest the matrix, and direct adjacent perichondral cells to become 
osteoblasts, which then secret a matrix rich in type I collagen and form a bone collar 
around the center of the cartilage template. Hypertrophic chondrocytes then undergo 
apoptotic cell death. The cartilage matrix provides a scaffold for osteoblasts to lay down 
bone matrix within it.  
1.4 Blood vessel invasion and ossification centers.  
VEGF and other angiogenic factors secreted by hypertrophic chondrocytes recruit 
endothelial cells from the surrounding blood circulation, and trigger vascular invasion 
from the periosteum[1]. This invasion brings osteoclasts and hematopoietic cells into 
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the mineralized cartilage. The newly recruited osteoclasts start to degrade the 
mineralized matrix. Osteoblasts are also recruited from the periosteum, and lay down a 
new bone-specific matrix on the remains of the hypertrophic cartilaginous matrix. With 
the formation of the early trabecular bone, the primary spongiosa is established from the 
middle of the growth plates and eventually develops into a primary ossification center 
(POC) (Figure 3). Another step in endochondral bone formation is the formation of 
secondary ossification centers (SOCs), which initiate at a late stage of development. 
These centers form in the middle of epiphyseal cartilage after establishment of the 
growth plates. 
 
Figure 3. The formation of secondary ossification centers.  
The secondary ossification centers (SOC) form in the middle of the epiphyseal cartilage after 
establishment of growth plates. At this point, the epiphyseal cartilage that is now separated from 
the growth plate by the SOC will eventually develop into articular cartilage at the far end of 
bone, which provides an important cushion during the whole adult life. The longitudinal growth 
of the bone continues to depend on the activity of the epiphyseal growth plates between primary 
and secondary ossification centers. In humans, the growth plates close during puberty and 
eventually determine adult height. The mechanisms leading to the formation of the secondary 
ossification centers are similar to the formation of primary ossification centers. (POC: primary 
ossification center). (Created according to [1-3].) 
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After formation of the secondary ossification center, the epiphyseal cartilage is now 
separated from the growth plate by the SOC and will eventually develop into articular 
cartilage at the far end of bone, which provides an important cushion during the whole 
adult life. The longitudinal growth of the bone continues to depend on the activity of the 
epiphyseal growth plates between primary and secondary ossification centers. In 
humans, it closes during puberty (when primary and secondary ossification centers fuse) 
and eventually determines adult height[2].  
The mechanisms leading to the formation of the secondary ossification centers are 
similar to the formation of primary ossification centers.  
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2. Autophagy. 
 
Autophagy is an important protein degradation pathway playing fundamental roles in 
tissue homeostasis and energy metabolism. It is defined as a tightly regulated membrane 
rearrangement process that ensures lysosome-dependent bulk degradation of cytosolic 
proteins and organelles such as the endoplasmic reticulum, mitochondria, peroxisomes, 
the nucleus and ribosomes. Evidence indicates that autophagic degradation promotes the 
recycling and salvage of cellular nutrients, thereby enabling cell survival during 
starvation or in response to environmental stresses[6].  
The term “autophagy” refers to a collection of tightly regulated catabolic processes, all 
of which deliver cytoplasmic components to the lysosome for degradation, and that are 
broadly classified into three pathways: macroautophagy, microautophagy and 
chaperone-mediated autophagy (Figure 4)[6], [7].  Macroautophagy involves the 
formation of double membrane-bound vesicles called autophagosomes that engulf 
cytoplasmic proteins and organelles; these autophagosomes are trafficked to lysosomes, 
where the sequestered cargo is degraded. Microautophagy refers to the invagination of 
the lysosomal or endosomal membrane, resulting in the direct engulfment of substrates 
that are subsequently degraded by lysosomal proteases. Chaperone-mediated autophagy 
is distinct from macroautophagy and microautophagy because cargo is not sequestered 
within a membrane-delimited vesicle. Instead, proteins targeted by chaperone-mediated 
autophagy contain a peptide motif that, once recognized by a cytosolic chaperone, 
promotes the translocation of these targets across lysosomal membranes into the 
lysosome. Macroautophagy (hereafter autophagy) is believed to be the major mode of 
autophagy, and is the most extensively analyzed in this thesis work.  
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Figure 4. Overview of autophagy pathways.  
In macroautophagy, initiation begins with the formation of the phagophore assembly site (PAS). 
This is mediated by the UNC51-like kinase (ULK) complex, which consists of ULK1, 
autophagy-related protein 13 (ATG13), FAK family kinase interacting protein of 200 kDa 
(FIP200) and ATG101. Further nucleation requires the class III PI3K complex, which is 
composed of the vacuolar protein sorting 34 (VPS34) PI3K, along with its regulatory subunits 
ATG14L, VPS15 and Beclin 1. Phagophore membrane elongation and autophagosome 
completion requires two ubiquitin-like conjugation pathways. The first produces the ATG5–
ATG12 conjugate, which forms a multimeric complex with ATG16L, whereas the second 
results in the conjugation of phosphatidylethanolamine (PE) to LC3 (the microtubule-associated 
protein 1 light chain 3). PE-conjugated LC3 (LC3–PE) is required for the expansion of 
autophagic membranes, their ability to recognize autophagic cargoes and the fusion of 
autophagosomes with lysosomes. The resulting autophagosome fuses with endocytic and 
lysosomal compartments, ultimately leading to formation of the autolysosome. In 
microautophagy, substrates are directly engulfed at the boundary of the lysosomal membrane. In 
chaperone-mediated autophagy, substrates with the pentapeptide motif KFERQ are selectively 
recognized by the heat shock cognate 70 kDa protein (HSC70) chaperone and translocated to 
lysosomes in a LAMP2A-dependent manner. In all three processes, the autophagic cargo is 
degraded via lysosomal hydrolases (adapted from [6]). 
 
 
2.1 Overview of the autophagic pathway. 
Two main kinase systems control the autophagic pathway: the mTOR-ULK1 and the 
Beclin 1 pathways. While the former is required to give the initiation signal to the 
autophagosome formation, the latter is required for properly vesicle nucleation. 
mTOR, or mammalian target of rapamycin, is an evolutionarily conserved Ser/Thr 
protein kinase central for integrating signaling pathways that regulate cellular 
homeostasis[8]. mTOR is the catalytic subunit of two functionally and structurally 
distinct complexes called mTOR complex 1 (mTORC1) and mTORC2 whose molecular 
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function will be described later.   
Beclin 1 is a coiled-coil protein involved in the regulation of autophagy in mammalian 
cells[9]. Beclin 1 binds to hVps34/class III phosphatidylinositol-3-kinase (PI(3)K) 
through its evolutionarily conserved domain (ECD). The hVps34/PI(3)K generates 
phosphatidylinositol-3-phosphate (PI(3)P), which has important roles in several 
membrane trafficking pathways, including the multivesicular body pathway, retrograde 
trafficking from endosomes to the Golgi and phagosome maturation[10].  
Autophagosome biogenesis. 
The earliest step of autophagy is characterized ultrastructurally by the sequestration of 
portions of cytoplasm into a double membrane-bound vesicle called the 
autophagosome. The autophagosome subsequently fuses with a lysosome, leading to the 
degradation of the sequestered cytosolic proteins and organelles. Studies in yeast have 
identified more than 30 AuTophagy-related Genes (ATGs), many of which have 
identified mammalian orthologues[7]. As depicted in Figure 1, autophagosome 
formation comprises three main steps: initiation, nucleation and expansion of the 
isolation membrane.  
Initiation/Nucleation. 
The process of autophagosome formation begins at the phagophore assembly site (PAS, 
also known as the isolation membrane) with the contribution of mTORC1 activity[7]. 
When activated in the presence of nutrients, the mTORC1 complex associates with the 
UNC51-like kinase (ULK) complex and hyperphosphorylates its subunits such as 
ULK1 on Serine 757 (S757) and Atg13, which results in its inactivation and subsequent 
down-regulation of autophagy. Conversely, nutrients deprivation downregulates 
mTORC1, which dissociates from the ULK1 complex, leading to its subsequent 
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dephosphorylation on specific residues and resulting in its activation. Once active, the 
ULK1 complex (which in addition to ULK1 and ATG13 is composed by FAK family 
kinase interacting protein of 200 kDa (FIP200) and ATG101) assembles to initiate 
autophagosome formation. The carboxy-terminal domain (CTD) of ULK1 binds to 
membranes, and this property might mediate the recruitment of the complex to the site 
of autophagosome initiation[11]. Furthermore, has been shown that autophagy is 
promoted by AMP activated protein kinase (AMPK), which is a key energy sensor and 
regulates cellular metabolism to maintain cellular homeostasis. Under glucose 
starvation, AMPK promotes autophagy by directly activating ULK1 through 
phosphorylation of Serine 317 (S317) and Serine 777 (S777). Under nutrient 
sufficiency, high mTORC1 activity prevents ULK1 activation by phosphorylating 
ULK1-S757 and disrupting the interaction between ULK1 and AMPK. This 
coordinated phosphorylation is important for ULK1 in autophagy induction[12].  
Equally important for initiating autophagosome formation is the autophagy specific 
class III PI3K complex (also known as Beclin1 complex), which is composed by a 
vacuolar protein sorting 34 (Vps34), p150, Beclin1 and ATG14[9]. Once activated and 
targeted to the site of autophagosome initiation, the PI3K complex produce an 
autophagosome-specific pool of PI(3)P, an essential membrane component of the 
elongating phagophore. ULK1 was recently shown to phosphorylate Vps34, and this 
enhances the activity of the PI3K complex[11]. These events drive the nucleation of the 
isolation membrane and the recruitment of additional ATG proteins and autophagy-
specific PI(3)P effectors, such as DFCP1 (double FYVE-containing protein 1) and WIPI 
(WD- repeat domain phosphoinositide-interacting), proteins that induce membrane 
rearrangements that ultimately facilitates the formation of autophagosomes.  
The Beclin1 core complex also interacts with UVRAG (UV irradiation resistance-
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associated gene). A proportion of UVRAG is present in a Beclin 1– UVRAG–Vps34–
Vps15 complex that normally excludes Atg14L. This mutual exclusion of Atg14L and 
UVRAG for Beclin 1 binding is likely to be due to the overlap of their docking sites on 
Beclin 1[13]. UVRAG was reported to act together with Beclin 1 to induce 
autophagosome formation. The expression of UVRAG was also correlated with an 
increase in Vps34 enzyme activity, suggesting a role for the Beclin 1–UVRAG–Vps34–
Vps15 complex in autophagy regulation. Negative regulators of Beclin1 activation has 
been described: RUN domain Beclin 1-interacting and cysteine-rich containing protein 
(Rubicon) and Bcl-2 (beta cell lymphoma 2). Rubicon binds Beclin 1, UVRAG and 
Vps34. In opposition to the role of Atg14L, Rubicon was found to suppress the 
UVRAG function in stimulating the kinase activity of Vps34 that contributes to 
autophagosome biogenesis[13].  
In addition some antiapoptotic members of the Bcl-2 family, such as Bcl-2 and BclxL, 
interact with Beclin 1. A series of investigations have shown that antiapoptotic Bcl-2 
proteins inhibit the autophagic function of Beclin 1 through binding to its BH3 domain, 
thereby suggesting that Bcl-2 family members also function as inhibitors for autophagic 
pathways[14]. A model was proposed that the Beclin 1–Bcl-2 complex is constitutively 
present and functions as a rheostat to maintain homeostasis of basal levels of autophagy. 
It has been shown that Bcl2, Beclin1, VPS34, UVRAG are present in the same 
complex. Protein phosphorylation can modulate the status of the Beclin1 complex, 
regulating Bcl2-Beclin1 mediated autophagic activity.  
Expansion  
Following nucleation, the ATG12–ATG5–ATG16L1 complex (also called the 
ATG16L1 complex) is recruited to the membrane, where it functions as an E3-like 
ligase to mediate the lipidation of microtubule-associated protein 1 light chain 3 
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(MAP1LC3; also known as LC3) with phosphatidylethanolamine and its family 
members GATE16 and GABARAP (GABA receptor-associated protein)[15]. This 
enables them to associate with the autophagosome membrane. The association of these 
cytosolic proteins and protein complexes with the membrane occurs while the isolation 
membrane is expanding. There are two ubiquitin-like systems that are key to 
autophagy[7]. In the first of these systems, Atg7 acting like an E1 ubiquitin activating 
enzyme activates Atg12 in an ATP-dependent manner by binding to its carboxyterminal 
glycine residue. Atg12 is then transferred to Atg10, an E2-like ubiquitin carrier protein 
that potentiates covalent linkage of Atg12 to lysine 130 of Atg5. Conjugated Atg5–
Atg12 complexes in pairs with Atg16L dimers to form a multimeric Atg5–Atg12–
Atg16L complex that associates with the extending phagophore. The association of 
Atg5–Atg12–Atg16L complexes is thought to induce curvature into the growing 
phagophore through asymmetric recruitment of processed microtubule-associated 
protein light chain 3 (LC3B-II). Atg5–Atg12 conjugation is not dependent on activation 
of autophagy and once the autophagosome is formed, Atg5–Atg12–Atg16L dissociates 
from the membrane, making conjugated Atg5–Atg12 a relatively poor marker of 
autophagy. The second ubiquitin-like system involved in autophagosome formation is 
the processing of LC3B. LC3B is expressed in most cell types as a full-length cytosolic 
protein that, upon induction of autophagy, is proteolytically cleaved by Atg4, a cysteine 
protease, to generate LC3B-I. The carboxyterminal glycine exposed by Atg4-dependent 
cleavage is then activated in an ATP-dependent manner by the E1-like Atg7 in a 
manner similar to that carried out by Atg7 on Atg12. Activated LC3B-I is then 
transferred to Atg3, a different E2-like carrier protein before phosphatidylethanolamine 
(PE) is conjugated to the carboxyl glycine to generate processed LC3B-II. Recruitment 
and integration of LC3B-II into the growing phagophore is dependent on Atg5–Atg12 
and LC3B-II is found on both the internal and external surfaces of the autophagosome, 
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where it plays a role in both hemifusion of membranes and in selecting cargo for 
degradation. The synthesis and processing of LC3 is increased during autophagy, 
making it a key readout of levels of autophagy in cells. It is proposed that LC3B-II, 
acting as a ‘receptor’ at the phagophore, interacts with ‘adaptor’ molecules on the target 
(eg protein aggregates, mitochondria) to promote their selective uptake and 
degradation[6]. The best-characterized molecule in this regard is p62/SQSTM1, a multi-
functional adaptor molecule that promotes turnover of polyubiquitinated protein 
aggregates.  
Fusion  
Newly synthesized autophagosomes then undergo extensive remodelling to acquire 
degradative capabilities. The remodelling process, also known as autophagosomal 
maturation, involves sequential fusion of autophagosomes with endocytic vesicles 
(early and late endosomes) and lysosomes, producing degradative autolysosomes. The 
sequestered material is then degraded into building blocks for synthesis of 
macromolecules and energy production.  
A prerequisite for vesicle fusion is vesicle tethering. The tethering events at the 
lysosomes have been thoroughly studied and shown to require the class C vacuolar 
protein sorting (Vps) complex[16]. The core class C Vps complex (hereafter referred to 
as C-Vps), including Vps11, Vps16, Vps18 and Vps33 exists into two configurations: 
the HOPS complex (for homotypic vacuole fusion and protein sorting), which contains 
two additional subunits (Vps39 and Vps41), acts at the vacuole, whereas the class C 
core vacuole/endosome tethering (CORVET) complex has Vps3 and Vps8 instead, and 
functions at the endosome. 
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Figure 5. Model of the role of UVRAG as a coordinator of the autophagosomal and 
endosomal machineries.  
At an early stage of autophagy, UVRAG targets Beclin1 to facilitate autophagosome formation, 
whereas at later stages, UVRAG interacts with C-Vps to promote autophagosome maturation. 
UVRAG–C-Vps is also involved in the endosome–lysosome transition by activation of Rab7 
(adapted from[16]).  
 
Has been demonstrated that mTORC1 regulates early stages as well as later stages of 
autophagy[17]. Independently of Beclin1, UVRAG interaction with C-Vps stimulates 
autophagosome maturation and endosomal fusion, thereby enhancing both autophagic 
and endocytic protein degradation (Figure 5). This interaction stimulates delivery and 
degradation of autophagic cargo through enhancing of Rab7 GTPase activity. The 
function of UVRAG to regulate the HOPS complex is antagonized by Rubicon [18].  
Under nutrient-enriched conditions mTORC1 binds and phosphorylates UVRAG at 
Ser497. UVRAG phosphorylation has a positive effect on the interaction between 
UVRAG and Rubicon, whereas it has a negative effect on the kinase activity of Vps34 
and the interaction between UVRAG and the HOPS complex (Figure 6). In addition, 
has been demonstrated that UVRAG-S497 phosphorylation suppresses the UVRAG-
ART ICLES
To further define UVRAG interaction with Vps16, UVRAG mutants 
containing deletions of C2, CCD or the entire C-terminal region were 
constructed for binding studies. The UVRAG$CCD mutant bound 
Vps16 as efficiently as wild-type UVRAG, whereas UVRAG∆N(1–147) and 
UVRAG∆270-CT showed substantially reduced Vps16 binding (Fig. 2d). 
This indicates that although the C2 or C-terminal region of UVRAG 
binds Vps16 sufficiently, the presence of the central Beclin1-binding 
CCD domain suppresses their Vps16 binding activity (Fig. 2d). However, 
Beclin1 overexpression did not negatively affect the UVRAG–C-Vps 
interaction (Supplementary Information, Fig. S1e). Furthermore, both 
UVRAG∆N(1–147) and UVRAG∆270-CT mutants retained efficient Beclin1-
binding capability (data not shown). Thus, the weak Vps16 binding of 
UVRAG∆N(1–147) and UVRAG∆270-CT mutants was probably not due to 
either their Beclin1 interaction or misfolding. Nevertheless, these results 
demonstrate that UVRAG contains two separate regions for Vps16 bind-
ing that are genetically distinct from Beclin1 interaction.
UVRAG enhances association of C-Vps with autophagosomes
Although UVRAG is part of the Beclin1–PI(3)KC3 complex for 
autophagy induction27, its direct association with autophagosomes has 
not yet been addressed. To this end, we expressed Flag–UVRAG, in 
combination with GFP–LC3, which specifically labels autophagic mem-
branes31, in HeLa cells. Rapamycin treatment caused a rapid shift in 
GFP–LC3 staining from a diffuse cytosolic/nuclear staining to a punc-
tate pattern outlining autophagic vacuoles in which UVRAG colocal-
ized substantially (Supplementary Information, Fig. S3a). To analyse 
whether UVRAG affected the distribution of C-Vps when autophagy 
was induced, HA–Vps16 and GFP–LC3 were expressed in HeLa.
Vector (HeLa.Vec) and HeLa.UVRAG cells (Fig. 3a). More than 70% 
of the LC3-labelled autophagosomes colocalized with HA–Vps16 in 
HeLa.UVRAG cells, whereas only partial colocalization was observed 
in HeLa.Vec cells (Fig. 3a). Similar results were obtained in HCT116 
cells, in which UVRAG expression is much lower due to a mono-allelic 
frameshift mutation32 (data not shown). In addition, small interference 
RNA (siRNA)-mediated depletion of UVRAG caused a significant 
reduction in the colocalization of GFP–LC3 with Vps16, suggesting that 
UVRAG expression effectively facilitates the recruitment of Vps16 onto 
autophagosome membranes (Supplementary Information, Fig. S3b). 
However, Vps16 depletion in HCT116 and HeLa cells stably expressing 
vector or UVRAG showed no discernable effect on UVRAG-mediated 
autophagosome formation (Fig. 3b). These data indicate that UVRAG 
efficiently recruits C-Vps to LC3+ autophagosomes; but C-Vps does not 
appear to act on UVRAG-mediated autophagosome formation.
Autophagosome maturation in UVRAG-expressing cells
Given that C-Vps in yeast acts as a tethering factor in vesicle fusion33, 
and that mutations in Drosophila homologues of C-Vps subunits induce 
autophagosome maturation defects25,26,34,35, we initially assessed the 
effects of UVRAG on autophagosome maturation by measuring the 
colocalization efficiency of GFP–LC3-labelled autophagosomes with 
LAMP1-stained late endosomes/lysosomes (Fig. 4a). The percentage 
of LAMP1+/LC3+ co-stained autophagosomes was significantly higher 
in HeLa.UVRAG than in HeLa.Vec cells, and was further enhanced by 
autophagy induction (Fig. 4a). However, treatment with bafilomycin A1, 
a specific inhibitor of vacuolar H+-ATPase, blocked the UVRAG-induced 
autophagosome maturation (Fig. 4a). Similar effects were observed when 
CD63 late endosomal protein was used as an autophagosome matura-
tion marker (Fig. 4b). As detected in HeLa cells, the fusion efficiency 
of GFP–LC3 with LAMP1+ or acidotropic LysoTracker Red+ late endo-
somes/lysosomes was approximately doubled in HCT116.UVRAG, 
compared with HCT116.Vector (HCT116.Vec) cells (Supplementary 
Information, Fig. S3c). Additionally, LC3+ vesicles sho ed higher 
proteolytic activity in UVRAG-expressing cells when compared with 
the control, as illustrated by enhanced staining with DQ-Red bovine 
serum albumin (BSA) whose fluorescence dequenches upon proteoly-
sis (Supplementary Information, Fig. S3d). Furthermore, the proteolysis 
rate of long-lived proteins in HeLa.UVRAG and HCT116.UVRAG cells 
during starvation was significantly accelerated, compared with that in 
control cells, but was markedly suppressed by bafilomycin A1 (Fig. 4c; 
data not shown). Together, these data indicate that UVRAG expression 
enhances autophagosome maturation or autophagic flux.
The roles of Beclin1 and C-Vps in UVRAG-mediated 
autophagosome maturation
As UVRAG interacts directly with Beclin1 through its CCD domain to 
induce autophagy, we evaluated whether Beclin1 interaction influenced 
UVRAG-mediated autophagosome maturation. HeLa and HCT116 cells 
expressing wild-type UVRAG, UVRAG$CCD or UVRAGCCD mutant were 
examined for autophagosome maturation level by measuring the colo-
calization efficiency of LC3+ vesicles with LAMP1+ late endosomes/
lysosomes. Consistent with our previous findings27, the UVRAG$CCD 
mutant, which lost Beclin1 binding, failed to induce autophagosome 
formation (Fig. 5a; Supplementary Information, Fig. S4). In contrast, 
the UVRAG$CCD mutant, which is able to interact with C-Vps, promoted 
autophagosome maturation as efficiently as wild-type UVRAG (Fig. 5a; 
Supplementary Information, Fig. S4). In addition, the UVRAGCCD 
mutant did not bind C-Vps and failed to induce autophagosome 
maturation (Fig. 5a; Supplementary Information, Fig. S4). Moreover, 
siRNA-mediated knockdown of Beclin1 led to a marked reduction of 
UVRAG-mediated autophagosome formation, but had a minimal effect 
on its autophagosome maturation activity (Supplementary Information, 
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Figure 8 Model of the role of UVRAG as a coordinator of the 
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autophagy, UVRAG targets Beclin1 to facilitate autophagosome formation, 
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mediated stimulation of the Vps34 kinase activity[17]. Consequently, it decreases the 
production of PI(3)P required for vesicles fusion and autophagosome maturation. 
Collectively, these findings define the mTORC1-UVRAG pathway as an important 
regulatory axis through which cells coordinate autophagy and the endosome-lysosomal 
degradation pathway. The coordinate regulation might be important to maintain normal 
cellular physiology under changing environments of growth factors and nutrients.  
 
Figure 6. Model of mTORC1 regulation of UVRAG function. 
In the absence of nutrients, UVRAG binding to the HOPS complex stimulates lysosomal fusion 
with autophagosome and endosome. Under nutrient-rich conditions mTORC1 binds and 
phosphorylates UVRAG. UVRAG phosphorylation has a positive effect on the interaction with 
its inhibitory partner Rubicon, and a negative effect on the kinase activity of Vps34 (adapted 
from [17]). 
 !
The available evidence indicates also that Rubicon acts at a later stage of the autophagic 
process. Because Rubicon contains a RUN domain, a conserved motif known to interact 
with and regulate small GTPases, one possibility is that Rubicon interacts with specific 
Rabs that were previously shown to regulate the autophagic process in the later stage of 
autophagosome-lysosome fusion, counteracting these step of the autophagic-lysosomal 
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pathway[18]. 
2.3 Signaling pathways that regulate autophagy. 
Autophagy is active at basal levels in most cell types where it is postulated to play a 
housekeeping role in maintaining the integrity of intracellular organelles and proteins. 
However, autophagy is strongly induced by starvation and is a key component of the 
adaptive response of cells and organisms to nutrient deprivation that promotes survival 
until nutrients become available again[19]. In mammals, a major intracellular hub for 
integrating autophagy-related signals is the mTOR-TFEB axis.  
mTOR is the catalytic subunit of two functionally and structurally distinct complexes 
called mTOR complex 1 (mTORC1) and mTORC2[8] (Figure 7). 
 
 
 
Figure 7. mTORC1 and mTORC2 complexes. 
The mTOR kinase nucleates two distinct protein complexes termed mTORC1 and mTORC2. 
mTORC1 responds to amino acids, stress, oxygen, energy, and growth factors and is acutely 
sensitive to rapamycin. It promotes cell growth by inducing and inhibiting anabolic and 
catabolic processes, respectively, and also drives cell-cycle progression. mTORC2 responds to 
growth factors and regulates cell survival and metabolism, as well as the cytoskeleton (adapted 
from [8]).  
 
Unique accessory proteins distinguish these complexes: regulatory-associated protein of 
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mTOR (Raptor) and rapamycin-insensitive companion of mTOR (Rictor) define 
mTORC1 and mTORC2, respectively. These companions function as scaffolds for 
assembling the complexes and for binding substrates and regulators.  
2.4 mTOR complex 1 (mTORC1). 
mTORC1 is activated by growth factors (for example, insulin), nutrients (amino acids) 
and the cellular energy status (high ATP/AMP ratio). Growth factors such as insulin 
stimulate mTORC1 through the PI3K–phosphoinositide-dependent kinase 1 (PDK1)–
AKT pathway[20]. Activated AKT phosphorylates tuberous sclerosis complex 2 
(TSC2) at multiple sites to inhibit the TSC complex (composed by several members) 
that acts as a GTPase-activating protein (GAP) for the small GTPase RAS homologue 
enriched in brain (Rheb). During inhibition of the TSC complex, GTP-loaded Rheb 
binds the mTOR catalytic domain to activate mTORC1 through an as yet unknown 
mechanism (Figure 8). Among regulators of mTORC1, amino acids contribution have 
until very recently been unclear. They represent the basic building blocks for protein 
synthesis, thus, both unicellular and multicellular organisms have evolved mechanisms 
to sense amino acids, import them into the cell when they are available, and synthesize 
new ones when they are lacking. 
For a long time, the understanding of amino acid regulation of mTORC1 remained 
confined to a few circumstantial observations, above all the fact that amino acids acted 
independently of the insulin/PI3K pathway.!
The nutrient signal to mTORC1 is transduced through the RAS-related GTP-binding 
protein (RAG) family of small GTPases [21], [22]. An active RAG heterodimer 
mediates the translocation of mTORC1 !from the cytoplasm to the surface of the 
lysosome, where mTORC1 encounters and! is activated by Rheb (Figure 8). 
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Figure 8. mTORC1 and the lysosomal surface. 
Growth factors stimulate mTORC1 through the PDK1–AKT pathway. Activated AKT 
phosphorylates tuberous sclerosis complex 2 (TSC2) at multiple sites to inhibit the TSC 
complex (composed by several members) that acts as a GAP for Rheb. During inhibition of the 
TSC complex, GTP-loaded Rheb binds the mTOR catalytic domain to activate mTORC1. 
Amino acids regulate the recruitment of mTORC1 to the lysosomal surface, where mTORC1 is 
activated. Under low amino acids (left) the v-ATPase-Ragulator-Rag GTPase complex is in the 
inactive conformation and is unable to bind to mTORC1, resulting in its cytoplasmic 
localization. Amino acids (right) signal to the v-ATPase–Ragulator complex and through them 
to the Rag GTPases, which switch their nucleotide loading and become activated. In turn, active 
Rag GTPases recruit mTORC1 to the lysosomal surface, where the small GTPase Rheb turns on 
the kinase activity of mTORC1. Active mTORC1 phosphorylates several targets, including 
S6K, 4E-BP1, ULK1 and the transcription factor TFEB. Phosphorylated S6K and 4E-BP1 favor 
protein synthesis; phosphorylation of ULK1 blocks autophagosome formation, whereas 
phosphorylation of TFEB prevents it from entering the nucleus and activating a catabolic 
transcriptional program. Adapted from [20]. 
 
Following the discovery of mTORC1, it was observed that withdrawal of amino acids 
from the culture media potently suppressed mTORC1 signaling in mammalian cells and 
yeast alike; moreover, suppressing mTORC1 by starvation or using its chemical 
inhibitor rapamycin strongly induced autophagy[23]. Thus, a feedback loop began to 
emerge, connecting amino acids, mTORC1, and autophagy in a mechanism that drives 
growth under nutrient abundance and mediates growth arrest under starvation 
conditions, allowing amino acid stores to be replenished. 
The Rag GTPases localize to lysosomal surface thanks to a platform composed by three 
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small proteins, LAMTOR1-3, collectively known as Ragulator, which reside on the 
lysosome [24]. Along with v-ATPase and other amino acid transporters they create the 
necessary and sufficient condition by which mTORC1 can sense nutrients and can be 
activated[25].  
Independently of the stimuli that activate mTORC1, readout of its function is the 
phosphorylation of key substrates such as ribosomal protein S6 kinase (p70-S6K), 
4eBP1 and ULK1. While the first two are directly implicated in the initiation of protein 
synthesis and translation, respectively, the latter, as described above, regulates 
autophagy initiation[8].  
The presence of mTORC1 at the lysosome has important implications for its ability to 
control autophagy. In non-starving cells, mTORC1 suppresses the formation of the 
phagophore by phosphorylating and inhibiting the kinase ULK1 and its interacting 
partner, ATG13. These effects depend on the Rag GTPases; expression of the active 
Rags suppresses autophagy under starvation conditions, whereas expressing the 
inhibitory mutants results in constitutive autophagosome formation[21]. 
2.5 Transcription factor EB (TFEB).  
Very recently, a novel paradigm has begun to emerge where the amino acid/mTORC1 
pathway centered at the lysosome may be part of a novel signaling mechanism that 
controls lysosomal gene expression and, through this process, affects cellular clearance 
and metabolism. A bioinformatics search for consensus binding sites in the promoters 
of lysosomal genes identified the coordinated lysosomal expression and regulation 
(CLEAR) element, which is bound by the MiT/TFE subfamily of helix–loop–helix 
(bHLH) transcription factors[26]. One member of the MiT/TFE family, known as 
transcription factor EB (TFEB), physically binds the CLEAR motif in the promoter of 
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multiple lysosomal genes, including luminal hydrolases and membrane transporters, to 
upregulate their expression. Overexpressing TFEB in cells led to a striking expansion of 
the lysosomal compartment, both in terms of size and number. This, in turn, resulted in 
enhanced clearance capacity towards multiple lysosomal substrates.  
Shuttling between the nucleus and the cytoplasm regulates the activity of TFEB. A key 
observation was that withdrawal of nutrients from the culture media induced the nuclear 
translocation of TFEB in cells. Among the transcriptional targets of TFEB are several 
autophagy-mediating genes and, accordingly, TFEB overexpression resulted in 
enhanced formation of LC3-positive autophagosomes. Conversely, siRNA-mediated 
TFEB depletion resulted in a defective autophagic response to nutrient starvation. These 
findings support a model where TFEB is a key component of a transcriptional 
starvation-response program. By expanding the lysosomal and autophagic 
compartments, this program increases the ability of cells to degrade and recycle their 
substrates, and thus to sustain adequate levels of energy and metabolites[27].  
mTORC1 exerts a tight control over the subcellular localization of TFEB: when cells 
are replete with nutrients, mTORC1 phosphorylates TFEB at two critical serines, 
sequestering TFEB in the cytoplasm[28]. A series of observations strongly suggest that 
the amino acids/mTORC1 pathway is especially important in controlling TFEB nuclear 
localization[29]. Treatments that cause starvation or lysosomal stress, including amino 
acid withdrawal, v-ATPase inactivation, and overexpression of transporters that empty 
the lysosome of its amino acid content, caused a massive translocation of TFEB to the 
nucleus. TFEB phosphorylation occurs on the lysosomal membrane, where mTORC1 
and TFEB physically bind to each other (Figure 8). Thus, the lysosome seems to 
operate as a ‘gate’ that controls the amount of TFEB allowed to reach the nucleus. In 
fully fed cells, active mTORC1 meets TFEB at the lysosome, phosphorylates it, and 
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releases it back into the cytoplasm. When mTORC1 is inactivated, it detaches from the 
lysosomal membrane, allowing TFEB to become unphosphorylated and move to the 
nucleus. This lysosome-to-nucleus signaling system may play a key role in coordinating 
cellular adaptation to growth-promoting, versus starvation, conditions[27].  
In comparison to mTORC1 regulation, mTORC2 regulation is poorly understood. Only 
growth factors stimulate mTORC2 kinase activity, which is mediated through PI3K-
dependent mTORC2–ribosome association[8]. The signaling steps beyond 
phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P3) in the activation of mTORC2 are 
unknown and distinct from those upstream of mTORC1. mTORC2 will not be further 
subject of study or discussion in this thesis work.   
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3. Autophagy in skeletal tissue.   
Recently the work done by our lab clarified the role of autophagy during skeletal 
growth[30]. We showed that autophagy is induced in growth-plate chondrocytes during 
post-natal development and regulates the secretion of type II collagen (Col2), the major 
component of cartilage ECM. Mice lacking the autophagy related gene 7 (Atg7) in 
chondrocytes experience endoplasmic reticulum storage of type II procollagen (PC2) 
and defective formation of the Col2 fibrillary network in the ECM. We observed 
induction of autophagy in growth plate chondrocytes during post-natal development. 
Notably, collagen production by chondrocytes was also increased at these ages, 
suggesting that the two processes could be co-regulated. After a screening of 
chondrogenic molecules for their potential to induce autophagy in vitro, we identify 
Fibroblast growth factor 18 (FGF18) as the only molecule that significantly increased 
autophagy flux. FGF signaling is among the most studied pathways in bone due to its 
involvement in many forms of skeletal disorders [31]. FGF18 plays a key role in 
skeletal growth and development in mice, regulating multiple aspects of chondrogenesis 
in the growth plate, including ECM composition [32]. Mice lacking FGF18 exhibited 
very low levels of autophagy in chondrocytes compared to control mice, pointing to 
FGF18 as a physiological regulator of chondrocyte autophagy. Among the different 
FGF receptors, in vitro and in vivo data suggest that FGF18 acts mainly through FGF 
receptor 4 (FGFR4), and to a lesser extent through FGFR3, to regulate autophagy. 
Fgf18+/- and Fgfr4-/- mice failed to induce chondrocyte autophagy during post-natal 
bone development and as a consequence displayed PC2 storage in the ER of 
chondrocytes and decreased Col2 levels in the ECM. Biochemical studies suggested 
that FGF18 induces autophagosome biogenesis through the autophagy initiation 
complex Vps34-Beclin1. When active, this complex produces PI(3)P which is essential 
for autophagosome biogenesis. Consistent with this model, we rescued autophagy in the 
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growth plates of Fgf18+/- mice by using TAT-Beclin1, a peptide able to enhance the 
activity of endogenous Beclin1 protein[33]. Notably, TAT-Beclin1 restored ECM 
matrix defects in Fgf18+/- and Fgfr4-/- mice, indicating autophagy as a physiological 
regulator of FGF-mediated bone growth. Thus, this study has identified a novel 
mechanism by which FGF signaling regulates post-natal bone development and 
demonstrates that autophagy is a developmentally regulated process necessary for bone 
growth (Figure 9)[30]. 
 
Figure 9. Proposed role of FGF-mediated induction of autophagy during bone growth.  
FGF signaling modulates multiple aspects of chondrogenesis and bone growth through the 
regulation of different intracellular pathways. During post-natal bone development, FGF18 
induces chondrocyte autophagy through the activation of the Beclin1-Vps34 complex via 
FGFR4 and c-Jun N-terminal kinases (JNK). The FGF-mediated induction of autophagy 
controls collagen homeostasis and ECM composition during postnatal bone growth. Adapted 
from [30]. 
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3.1 mTORC1 in skeletal growth. 
As described above, a major signaling hub for autophagy regulation is mTORC1. In the 
course of my PhD, experimental evidence were published showing that although 
mTORC1 activity is required for chondrocyte growth and proliferation, its inactivation 
is essential for proper chondrocyte differentiation[34]. In addition, it has been showed 
that inactivation of the gene encoding either mTOR or Raptor (a component of mTOR 
complex 1) in the entire limb clearly causes growth retardation[35]. Furthermore, 
rapamycin induces mild growth retardation when administrated either systemically or 
locally, an effect primarily linked to attenuation of chondrocyte hypertrophy and 
decreased production of extracellular matrix [35], [36]. Whether activation of 
autophagy or another mTORC1-mediated function(s) is involved remains to be 
elucidated. So far, a transcriptional hypothesis has been proposed[34]: Bo Yan et al. 
showed that mTORC1 activity is required for chondrocyte growth and proliferation, but 
declines during the process of differentiation in vitro and in vivo. Low mTORC1 
activity is necessary for chondrocyte differentiation and maturation. Hyperactivation of 
mTORC1 in chondrocytes uncouples the normal proliferation and differentiation 
programme within the growth plate, leading to impairment of chondrocyte hypertrophic 
and terminal differentiation, chondrodysplasia and dwarfness in mice. Mechanistically, 
mTORC1 activation promotes the nuclear accumulation of a transcription factor 
(Gli1/2) required for the transcription of PTHrP; PTHrP is a key signaling molecule for 
bone growth by promoting chondrocyte proliferation and preventing chondrocyte 
hypertrophic and terminal differentiation. 
Neither the role of mTORC1 as principal regulator of autophagy nor the autophagic 
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status of chondrocytes have been taken in consideration in this context; besides, given 
the fundamental role of autophagy during skeletal growth it is reasonable to expect 
finely tuning of these two pathways during bone development. Thus oscillations in 
mTORC1 activity, that have been described for the bone either in physiological and 
pathological conditions, suggest a consequent impact on autophagy that still needs to be 
elucidated. 
Furthermore, even though the role of autophagy during bone growth has been 
successfully addressed, the lack of information about its regulation and contribution in 
pathological conditions prompted us to investigate in this direction.  
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4. Lysosome and Proteasome players of cellular metabolism. 
Macromolecule biosynthesis and degradation must be coordinated to maintain cell and 
tissue homeostasis.  The main degradation stations of the cells are lysosomes and 
proteasomes, organelles deputed to the digestion of cargoes into elementary units that 
can be either recycled or used to generate energy during period of nutrient shortage[37]. 
Moreover, protein degradation controls processes like the cell cycle, signaling, DNA 
transcription, repair and translation, by downregulating their critical regulatory 
elements. The two major pathways by which these organelles exert their function are: 
- Lysosome: autophagy is responsible for degradation of most long-lived proteins, but 
also aggregated proteins as well as whole cellular organelles. 
- Proteasome: the ubiquitin proteasome system (UPS) is responsible for degradation of 
most of the cellular proteins including the short-lived and the damaged ones. 
Autophagy and UPS are two cornerstones of cellular catabolism that are involved in 
most aspects of normal physiology and development, and are also implicated in a broad 
array of pathological states[37]. Their critical role in the maintenance of cellular 
homeostasis, suggests that their activities need to be carefully orchestrated[38]. 
 
4.1 Lysosome. 
 
In the mid-1950s, Christian de Duve discovered the lysosome as a vacuolar structure 
that contains various hydrolytic enzymes, which function optimally at an acidic pH. The 
definition of the lysosome has been broadened over the years. Lysosomes are organelles 
delimited by a single membrane and filled with digestive enzymes that are able to 
degrade molecules and structures into their elementary constituents[39]. Therefore they 
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represent the final destination for many endocytic and autophagic secretion molecules 
targeted for degradation or recycling. Furthermore lysosomes are involved in various 
specific cellular pathways such as autophagic degradation of molecules, matrix 
modelling, pathogen defence and plasma membrane repair via lysosomal 
exocytosis[27].  
Lysosomes originate from the fusion between endosomes and the Golgi’s hydrolytic 
vesicles. The Golgi’s hydrolytic vesicles, also called primary lysosomes, already 
contain all necessary hydrolases, but their local pH is not sufficiently acidic for their 
activation. Therefore lysosomal enzymes are activated only after the primary lysosome 
fuses with endosomes, as the latter carries proton pumps necessary for the acidification 
of the lumen.  
Lysosomes are involved in the degradation of a wide variety of structurally diverse 
substances into their basic building blocks, such as proteins, glycosaminoglycans 
(GAGs), sphingolipids, glycogen, nucleic acids, oligosaccharides and complex lipids. 
These are either recycled through biosynthetic pathways or further degraded to generate 
energy. Cellular and foreign material destined for degradation reach lysosomes via 
endocytosis, phagocytosis, autophagy, or direct transport.  
4.2 Lysosomal storage disorders (LSDs). 
Lysosomal storage disorders (LSDs) are characterized by progressive accumulation of 
undigested macromolecules within the cell due to lysosomal dysfunction[40].  
So far, LSDs are recognized as a cohort of nearly 60 different inherited disorders, with 
each sharing a genetic defect that renders the lysosomal system dysfunctional and 
unable to degrade specific materials normally processed within the cell. As a 
consequence, many tissues and organ systems are affected, including brain, viscera, 
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bone and cartilage. Whereas clinical features of these disorders vary widely, most are 
fatal within the first two decades of life following many years of worsening disease. 
The progressive nature of phenotype development is one of the hallmarks of LSDs. 
Lysosomal storage disorders (LSDs) affects many organs, included the skeleton[41]. 
The most prevalent LSD's with skeletal abnormalities are the mucopolysaccharidoses 
(MPSs)[42]. Mucopolysaccharidoses (MPSs) are caused by deficiency of a specific 
lysosomal enzyme, consisting of seven subtypes. In MPSs, the breakdown of the 
glycosaminoglycans (GAGs), chondroitin sulfate (CS), dermatan sulfate (DS), heparan 
sulfate (HS), keratan sulfate (KS) and/or hyaluronan is disrupted. Accumulation of 
undegraded GAG(s) is observed in multiple tissues, leading to broad clinical 
manifestations including mental retardation, skeletal dysplasia, corneal clouding, 
abnormal facies, coarse hair, hernia, hepatosplenomegaly, respiratory and heart valvular 
diseases, and abnormal joint mobility.  
MPS varies from severe systemic bone dysplasia to a lesser form of the disease that 
includes mild bone involvement, depending upon MPS type and clinical phenotype[43]. 
MPS patients with skeletal dysplasia (dysostosis multiplex) have deformity of the spine 
(lumbar gibbus, kyphoscoliosis), deformity of the chest (pectus carinatum, flaring of the 
rib cage), abnormal joint mobility, abnormal gait, short trunked dwarfism, and/or genu 
valgum. Patients may require a series of orthopedic surgeries (cervical decompression 
and fusion, femoral or tibial osteotomy, hip reconstruction and replacement etc.) 
throughout all their life.  
The pathophysiology is not completely understood, and likely involves a complicated 
interplay of storage, inflammation and epigenetic factors[40]. Better understanding of 
the etiology is of increasing importance, since recently developed treatments such as 
enzyme replacement therapy (ERT) for several of the MPS's and hematopoietic stem 
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cell transplantation (HSCT) for MPS I appear to have limited effect on skeletal 
disease[44]. ERT is approved for use in patients with MPS I, MPS II, MPS IVA, and 
MPS VI. Patients treated with ERT show clinical improvement of somatic 
manifestations and improved quality of life. However, there are several limitations with 
current ERT: i) limited effect on skeletal symptoms (one possibility is due to the limited 
penetration of enzyme into avascular cartilage), ii) rapid clearance from the circulation, 
and iii) immunological issues (antibody production leads to reduced therapeutic 
efficacy). To resolve the above issues, a long circulating or bone-targeting enzyme was 
devised to deliver the enzyme to bone [45]. The earlier that ERT is performed in animal 
models and human patients, the better the outcome. 
On the other side, potential advantages of HSCT for treating MPSs are that marrow-
derived donor cells could provide a continuous source of secreted enzyme, and also 
provide access of enzyme to bone and cartilage that is close to the bone marrow. 
However, has been proposed that secreted enzyme may not penetrate into the bone after 
HSCT [46]. Skeletal pathology from surgical remnants shows almost complete 
clearance of storage materials in chondrocytes with normal level of blood HS and DS. 
Thus, even though pathology in chondrocytes appeared to be normalized, there was 
incomplete correction of the skeletal phenotype by HSCT. The reasons for the 
continued skeletal phenotype are not known, but it is possible that irreversible bone 
abnormalities may have already occurred prior to transplantation or that the structure of 
the extracellular matrix remains abnormal [44].  
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4.3 Mucopolysaccharidosis and treatment options. 
Mucopolysaccharidosis type VII (MPS VII) 
In mucopolysaccharidosis type VII (MPS VII; Sly syndrome)[47] the GAGs, dermatan 
sulfate, heparan sulfate, chondroitin 4-sulfate, and chondroitin 6-sulfate, accumulate in 
lysosomes in the absence of the catabolic enzyme β-glucuronidase (GUSB). MPS VII is 
characterized by short stature, dysmorphic features, corneal clouding, hepatomegaly, 
skeletal abnormalities collectively referred to as dysostosis multiplex, and 
developmental delay. These clinical manifestations become progressively worse over 
time if left untreated. MPS VII patients with the most severe phenotype have hydrops 
fetalis prenatally and often are stillborn or survive only a few months. At the other 
extreme, patients with attenuated manifestations of MPS VII have survived into the fifth 
decade of life.  
Murine models of MPS VII have characteristics similar to the human disease[47]. MPS 
VII mice show GAG storage in lysosomes of visceral organs, skeleton, and brain. They 
have facial dysmorphism, growth retardation, deafness, behavioral deficits, and a 
shortened lifespan.  
Mucopolysaccharidosis type VI (MPS VI) 
Mucopolysaccharidosis type VI[48] is caused by deficiency of the enzyme arylsulfatase 
B [ARSB] (N-acetylgalactosamine-4-sulfatase) which removes the C4 sulfate ester 
group from the N-acetylgalactosamine sugar residue at the nonreducing terminus of the 
glycosaminoglycans dermatan sulfate (DS) and chondroitin sulfate (CS). Deficiency of 
ARSB results in intralysosomal storage and urinary excretion of these partially 
degraded GAGs. MPSVI shows a wide spectrum of symptoms ranging from slowly to 
rapidly progressing forms. It is characterized by characteristic skeletal dysplasia 
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(including short stature, dysostosis multiplex and degenerative joint disease), cardiac 
valve disease, reduced pulmonary function, hepatosplenomegaly, sinusitis, otitis media, 
hearing loss, sleep apnea, corneal clouding, carpal tunnel disease, and inguinal or 
umbilical hernia. Although intellectual deficit is generally absent in MPS VI patients, 
central nervous system findings may include cervical cord compression caused by 
cervical spinal instability, meningeal thickening and/or bony stenosis, communicating 
hydrocephalus, optic nerve atrophy and blindness. Clinical presentation of MPSVI 
varies greatly with respect to age of onset and rate of disease progression. Rapidly, 
intermediate and slowly progressing forms have been described, varying both in the 
severity and timing of symptoms development. Rapidly progressing forms may be 
evident since birth with elevated urinary GAGs, severe dysostosis multiplex, short 
stature, and death before the 2nd or 3rd decades. A slowly progressing form has been 
described as having later onset, mildly elevated urinary GAGs, mild dysostosis 
multiplex, with death in the 4th or 5th decades. 
Mucopolysaccharidosis type I (MPS I)  
Mucopolysaccharidosis-I (MPS I)[49] is a prototypical LSD caused by deficiency of a 
single lysosomal enzyme and occurs at a frequency in the range of 1:100.000. The 
disease is caused by homozygous inactivating mutations of the IDUA gene, encoding α-
l-iduronidase, an enzyme required for degradation of heparan and dermatan sulfate, 
representing two highly abundant GAGs. Depending on the type of mutation, there is a 
wide range of disease severity. The most severe forms of MPS-I (commonly termed 
Hurler syndrome) are characterized by mental retardation, hepatosplenomegaly, 
dysostosis multiplex, corneal clouding, cardiac dysfunction and death within the first 
decade of life. The mildest forms (commonly termed Scheie syndrome) are 
characterized by normal intelligence and life expectancy, yet corneal clouding, 
dysostosis multiplex and mild visceral storage are still causing serious problems in the 
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affected patients.  
Therapies for LSDs. 
Few therapies are available for LSDs, and treatments are mostly symptomatic as they 
are not able to completely revert the pathologic phenotype. There are different clinical 
trials mainly based on enzyme replacement therapy, bone marrow transplantation, ex-
vivo and in-vivo gene therapy, enzyme enhancement therapy and substrate 
reduction[50].  
However the lack of complete knowledge of the pathogenic mechanisms behind the 
disease is still problematic when developing new therapeutic approaches for the 
treatment of LSDs.  
In recent years biochemical and cell biology studies of LSDs have revealed an ample 
spectrum of abnormalities in a variety of cellular functions. These include defects in 
signaling pathways, calcium homeostasis, lipid biosynthesis and degradation and 
intracellular trafficking[51]. Therefore, an emerging view to explain the disease cascade 
is now focused on the importance of the multiple endosomal and autophagosomal 
streams flowing into the lysosomal system for processing. Failure to degrade and 
recycle sequestered materials in lysosomal disease may also lead to deficiency states in 
which precursors for metabolic pathways in the cell are diminished, followed by altered 
synthetic pathways and an increased metabolic demand on affected cells. The lysosomal 
system has thus emerged from being considered only an end-organelle, to being at the 
very hub of metabolic regulatory control. Perhaps the best example of the 
interconnection of the lysosome with other cellular systems is autophagy[52].  
Considering the highly integrated function of lysosomes and autophagosomes it was 
reasonable to expect that lysosomal storage in LSDs would have an impact upon 
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autophagy [53].  
In the last years, genome-wide association study (GWAS) has demonstrated that defects 
in the autophagy-lysosomal pathway are associated with bone size and stature in 
humans[54], [55], suggesting that the autophagic-lysosomal pathway plays an important 
role in bone homeostasis and development. The understanding of the biological and 
molecular system that links autophagy dysfunction and bone growth impairment has to 
be elucidated and it can further expand the possibility to treat bone defects in 
lysosomal-autophagy related disorders. Also, since the available therapies seem to have 
limited effects on bone defects in LSDs, it’s clear how important is to develop new 
therapeutic pharmacological tools to treat bone diseases. 
4.4 Proteasome. 
 
The 26S proteasome, often called “the proteasome”, is a multicatalytic enzyme complex 
expressed in the nucleus and cytoplasm of all eukaryotic cells[37]. The primary function 
of the proteasome is to degrade proteins. Proteasome substrates include signaling 
molecules, tumor suppressors, cell-cycle regulators, transcription factors and inhibitory 
molecules, among others. For a protein to be recognized by the proteasome, a small 
peptide (ubiquitin; Ub) must first be attached to the target protein. This process is 
carried out by a cascade of enzymes that activate free ubiquitin and carry it to the target 
protein[56].  
The pathway by which proteins are ubiquitinated and degraded by the proteasome is 
termed the ubiquitin–proteasome pathway (UPS). The proteasome is a complex of ~33 
different proteins that are arranged in an elongated particle composed of a central core 
with cap structures at one or both ends. It is a multicatalytic protease complex 
consisting of the 20S core particle (CP) and the 19S regulatory particles (RPs). The 20S 
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CP is composed of several subunits with distinct peptidase activities. The 19S is 
responsible for the recognition, unfolding, and subsequent translocation of ubiquitinated 
substrates into the 20S CP. This process is accompanied by enzymatic removal of Ub 
moieties, which are recycled. The proteasome is widely distributed in the cell, is 
localized to the cytosol and nucleus, and is also found tethered to several subcellular 
organelles. It is highly abundant, composing ∼1% of the total protein mass of cells[57].  
Recently, a new cross talk connecting mTORC1 and proteasome has emerged[58]. 
Manning et al described a mechanism by which through the involvement of the 
proteasome, mTORC1 exerts a coordinated regulation of protein synthesis and 
degradation.  They show that as well as increasing protein synthesis, mTORC1 
activation in mouse and human cells also promotes an increased capacity for protein 
degradation.  Cells with activated mTORC1 exhibited elevated levels of intact and 
active proteasomes through a global increase in the expression of genes encoding 
proteasome subunits. They hypothesized that, in addition to serving as a quality control 
mechanism for newly translated proteins, the enhanced proteasome activity upon 
mTORC1 activation could serve to maintain adequate pools of amino acids to sustain 
new protein synthesis.  
Given the tight regulation of mTORC1 on autophagy it is reasonable to expect a fine 
interplay that involves lysosome and proteasome in orchestrating cellular energy 
demand[38].  
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Aim of the thesis 
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The observation that mutations in more than 20 genes encoding for lysosomal proteins 
causes defects in skeletal development suggests that the lysosome may be involved in 
the regulation of intracellular signaling during skeletogenesis.  
When I started working on my PhD project little if anything was know about this 
regulation. Thus I started my work on LSD mouse models, which were previously 
shown to be characterized by severe skeletal abnormalities similar to those found in 
human patients. 
The main goals of this thesis project were to identify the mechanism(s) that 
underlie the skeletal manifestations of LSDs and to develop a therapeutic 
treatment.  
In the course of my PhD, our lab published a work showing that autophagy is a 
developmentally regulated process required for bone growth. My work started with the 
aim to extend these findings; exploring the possibility that autophagy dysfunction may 
be implicated in the pathogenesis of skeletal disorders.  
Defective autophagy is a generalized phenomenon occurring in many LSDs, although 
the pathogenic mechanisms are still unclear. By combining the knowledge of signaling 
that conveys on lysosome (the mTORC1-autophagy axis), I focused on the impaired 
lysosomal function to unravel the contribution of mTORC1 in bone growth. 
The thesis will cover two main topics: 
1) To characterize the contribution of mTORC1 signaling in the autophagy dysfunction 
found in LSD chondrocytes, thereby drawing a potential pathogenic mechanism. 
2) To apply the deriving knowledge towards genetic and pharmacological approaches to 
rescue impaired mTORC1 signaling and consequently bone growth in LSDs mouse 
models. 
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Material and Methods 
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1. In vivo 
Animals. 
The Gusb-/- line carrying the missense E536Q mutation was kindly shared by W. Sly (St 
Louis University). The Raptorflox/flox line was purchased from Jackson Laboratories 
(stock no. 013188). The CMV-Cre line was from A. Ballabio (TIGEM, Pozzuoli). 
Raptor flox/flox were mated with CMV-Cre to obtain heterozygous mice that were 
subsequently mated with Gusb+/- mice. Double heterozygous Gusb+/-;Raptor+/- mice 
were then mated with Gusb+/- in order to obtain Gusb-/-;Raptor+/-. Arsb-/- line was kindly 
shared by A. Auricchio (TIGEM, Pozzuoli). All mice used were maintained in a 
C57BL/6 strain background. The number of mice used in each experiment is specified 
in figure legends. Sex of the mice was not taken into account until post-natal day 15. 
Mice were randomly assigned to treatment groups. The investigators were not blinded 
to allocation during experiments and outcome assessment. Experiments were conducted 
in accordance with the guidelines of the Animal Care and Use Committee of Cardarelli 
Hospital in Naples and authorized by the Italian Ministry of Health. 
 
Skeletal staining. 
Skeletons were fixed in 95% ethanol overnight and stained with alcian blue and alizarin 
red (Sigma Aldrich) according to standardized protocols (http://empress. 
har.mrc.ac.uk/browser/). Alizarin red stains calcium and calcified structures, whereas 
alcian blue stains acetic mucins enriched in cartilage, thus the resulting colored skeleton 
will be red in bony parts and blue in cartilaginous parts. Measurement of bone length 
was performed using the Leica M205 A stereo microscope equipped with LAS X 
Software. 
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Tissue histology, immunohistochemistry and immunofluorescence. 
 
Histology was performed according to standardized procedures (http://empress.har.mrc. 
ac.uk/browser/). Briefly, femurs were fixed overnight in 4% (wt/vol) paraformaldehyde 
(PFA) and then demineralized in 10% EDTA (pH 7.4) for 48 h. Specimens were then 
dehydrated, embedded in paraffin and sectioned at 7 µm, and stained with haematoxylin 
and eosin. 
Collagen type II, type X and phospho-S6 ribosomal protein. PIER (proteolytic induced 
epitope retrieval) was performed as antigen retrieval method. Deparaffinised sections 
were treated with 1mg/ml pepsin at 37 °C for 20 minutes then with testicular 
hyaluronidase (2 mg/ml, Sigma Aldrich) at 37 °C for 60 min for Collagen type X or 
with chondroitinase ABC (Sigma) for 2 hours at 37°C for Collagen type II, washed in 
PBS and incubated in 3% H2O2 in methanol. Sections were incubated with diluted 
normal blocking serum for 20 minutes and overnight at 4°C with monoclonal antibody 
to collagen X (clone X53, Quartett, Berlin, Germany), collagen II (II-II6B3) 
(Hybridoma Bank) or Phospho-S6 Ribosomal Protein (Ser240/244) (Cell Signaling). 
P62-SQSTM1. For immunofluorescence, femurs were dissected from euthanized mice 
and fixed with buffered 4% PFA overnight at 4 °C, then washed with PBS and cryo-
protected in successive sucrose solutions diluted with PBS (10% for 2 h, 20% for 
several hours and 30% overnight at 4 °C; all wt/vol), and finally embedded in OCT 
(Sakura). Cryostat sections were cut at 10µm. Sections were blocked and permeabilized 
in 3% (wt/vol) BSA, 5% fetal bovine serum (FBS) in PBS plus 0.3% Triton X-100 for 3 
h and then incubated with the primary antibody (p62-SQSTM1, Progen) overnight. 
Sections were washed three times with 3% BSA in PBS plus 0.3% Triton X-100 and 
then incubated for 3 h with secondary antibodies conjugated with Alexa Fluor 568.  
Growth Plate measurement. Individual zonal heights were measured for the 
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morphologically defined proliferative and hypertrophic zones of the growth plate. The 
proliferative zone (PZ) is defined as the region of chondrocyte displaying flattened-disc 
morphology. The hypertrophic zone (HZ) is defined as the region beginning with the 
consistent cylindrical cellular profile and extending to the metaphyseal chondro-osseous 
junction. We have estimated PZ and HZ heights measuring the length between the 
initial and final proliferating and hypertrophic chondrocytes respectively, by CellSens 
software (Olympus Life Science; manual measurement). 
Collagen quantification and analysis. 
Colorimetric assay. This was performed using the Sircol soluble collagen assay 
(Biocolor) following the manufacturer’s protocol. Briefly, femoral cartilages were 
isolated from two/three mice with the same genotype, pooled and homogenized in 0.5 
ml of 1 mg/ml cold (4 °C) pepsin in 0.2M NaCl, 0.5M acetic acid to pH 2.1 with HCl 
and then digested at 4 °C for 24 h, twice. The pellet was discarded and an equal volume 
(1 ml) of 4 M NaCl in 1M acetic acid was added to precipitate collagen. The pellet was 
then resuspended in 0.8 ml of 0.2M NaCl in 0.5M acetic acid and was precipitated again 
two times. After the last precipitation the pellet was washed twice with 70% EtOH to 
remove residual NaCl. The pellet was then complexed with Sircol dye (the dye reagent 
contains Sirius Red in picric acid and has been formulated for specific binding to 
collagen). Absorbance was measured at 555nm and concentration was calculated using 
a standard curve. Values were normalized to DNA levels calculated measuring the 
absorbance at 260 nm.  
2. In vitro 
Transmission electron microscopy.  
For EM analysis, growth plates were fixed in 1% glutaraldehyde in 0.2M HEPES 
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buffer. Small blocks of growth plates were then post-fixed in uranyl acetate and in 
OsO4. After dehydration through a graded series of ethanol, tissue samples were cleared 
in propylene oxide, embedded in Epoxy resin (Epon 812) and polymerized at 60 °C for 
72 h. For pre-embedding immuno-EM RCS cells were fixed, permeabilised and labelled 
as described previously[59]. Anti-human LAMP-1 antibody was purchased by Sigma 
(Cat N-L1418). From each sample, thin sections were cut with a Leica EM UC6 
ultramicrotome and images were acquired using a FEI Tecnai-12 electron microscope 
(FEI, Eindhoven, Netherlands) equipped with a VELETTA CCD digital camera (Soft 
Imaging Systems GmbH, Munster, Germany).  EM analysis was performed by Elena 
Polishchuk in the “Advance Microscopy and Imaging core” at TIGEM, Pozzuoli. 
Cell culture, transfections and plasmids.  
Primary cultured chondrocytes were prepared from rib cartilage of P5 mice. Rib cages 
were first incubated in DMEM (Euroclone) using 0.2% collagenase D (Roche) and after 
adherent connective tissue had been removed (1.5 h) the specimens were washed and 
incubated in fresh collagenase D solution (3mg/ml) for a further 4.5 h. Isolated 
chondrocytes were maintained in DMEM supplemented with 10% FBS, 1% 
penicillin/streptomycin (Invitrogen). Adult fibroblasts were prepared from skin of P5 
mice. Samples, cut in small pieces using a razor blade, were first incubated with 
collagenase (30 min) and then were washed and incubated in trypsin for 20 min. After 
centrifuging, cell pellet was resuspended in complete medium. MPSI mesenchymal-
derived chondrocytes were provided by M. Serafini (University of Milano-Bicocca). 
ArsbKO HeLa cell line was provided by J. Monfregola (TIGEM, Pozzuoli). For amino 
acid starvation and stimulation experiments the cell culture medium was amino acid 
free RPMI 1640  (US Biological) supplemented with 10% dialyzed FBS (Invitrogen). 
Cells were rinsed twice with starvation medium then kept in a full volume of starvation 
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medium for 50 min. At 50 min time point a standard amino acids mixture comprising 
MEM non-essential amino acids solution, MEM essential amino acids solution and L-
Glutamine (Invitrogen) was added back to a final concentration of 3X for the indicated 
time points. Unless otherwise specified, to synchronize mTORC1 signaling before 
performing the experiments, primary chondrocytes and RCS cells were stimulated with 
A.A. for 24h and 6h, respectively. Cells were transfected with Lipofectamine LTX and 
Plus reagent (Invitrogen) following a reverse transfection protocol. The tandem mRFP–
GFP–LC3 plasmid was from T. Yoshimori (Osaka University, Japan). The myc-
UVRAG plasmid was from DH. Kim (University of Minnesota, USA). The GFP-
2xFYVE plasmid was from S. Tooze (Francis Crick Institute, London)  
Cell immunofluorescence.  
Chondrocytes were fixed for 10 min in 4% PFA in PBS and permeabilized for 30 min in 
0.05% (w/v) saponin, 0.5% (w/v) BSA, 50mM NH4Cl and 0.02% NaN3 in PBS 
(blocking buffer). For the detection of endogenous LC3 cells were methanol-fixed. The 
cells were incubated for 1h with the primary antibodies against Lamp-1 (Santacruz 
biotechnology), SQSTM1-p62 (Progen), mTOR (Cell Signaling), LC3 (Novus 
Biologicals) and WIPI-2 (Abcam) washed three times in PBS, incubated for 1 h with 
the secondary (Alexa Fluor-labelled) antibody, washed three times in PBS, incubated 
for 20 min with 1 µg/ml Hoechst 33342 and finally mounted in Mowiol. For the 
detection of TFEB and TFE3 cells were permeabilized for 30 min in 0.2% Triton X-100 
in PBS and blocked for 1 h with 0.1% Triton X-100, 10% goat serum in PBS. The cells 
were incubated overnight with primary antibodies against TFEB (MyBioSource) and 
TFE3 (Bethyl). All confocal experiments showing co-localization were acquired using 
slice thickness of 0.5µm using the LSM 710 confocal microscope equipped with a 63 × 
1.4 numerical aperture oil objective. Co-localization analysis was performed using the 
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ImageJ software (JaCoP plug-in). 
Western blotting.  
Cells were washed twice with PBS and then scraped in lysis buffer (RIPA lysis buffer 
[20 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium 
deoxycholate] in the presence of PhosSTOP and EDTA-free protease inhibitor tablets; 
Roche). Cell lysates were incubated on ice for 30 min and then the soluble fraction was 
isolated by centrifugation at 14,000 r.p.m. for 20 min at 4 °C. Total protein 
concentration in cellular extracts was measured using the colorimetric BCA protein 
assay kit (Pierce Chemical). Protein extracts, separated by SDS–PAGE and transferred 
onto membranes, were probed with antibodies against phospho (p)-p70S6K (T389), 
p70S6K, (p)-ULK1 (S757; S555; S317), ULK1, raptor (Cell Signaling), LAMP-1 
(Abcam), LC3B, β-actin (Novus Biologicals), P62/SQSTM1 (Abnova). Proteins of 
interest were detected with horseradish peroxidase (HRP)-conjugated goat anti-mouse 
or anti-rabbit IgG antibody (Vector Laboratories) and visualized with the Super Signal 
West Dura substrate (Thermo Scientific), according to the manufacturer’s protocol. The 
western blotting images were acquired using the Chemidoc-lt imaging system (UVP) 
and band intensity was calculated using ImageJ software using the ‘Gels and Plot lanes’ 
plug-in.  
Generation of Gusb-/- RCS cell line.  
To create Gusb gene disruption an RCS chondrocyte cell line was used. 1x106 cells 
were transfected with an all-in-one vector contains the sgRNA of interest (target site 
sequence: CACCTTGAGTTCCCGCGAAG with predicted no off-targets), which 
expression was driven by the U6 promoter, a recombinant form of Cas9 protein under 
the control of the CMV promoter and a mCherry reporter gene under the control of the 
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SV40 promoter (Genecopoeia). Cells were transfected with Lipofectamine LTX and 
Plus reagent (Invitrogen) following a reverse transfection protocol. 48h after 
transfection, putative positive clones were FACS sorted for the mCherry expression 
using the BD FACSAria. Sorted cells were kept in culture until confluence and then 
subjected to PCR analysis followed by Sanger sequencing to identify mutations. 
Positive clones were screened for β-gluronidase activity. Briefly, cell pellets were lysed 
in extraction buffer [50 mM NaHPO4, pH 7.0, 10 mM 2-mercaptoethanol, 10 mM 
Na2EDTA, 0.1% sodium lauryl sarcosine, 0.1% Triton X-100(100 ml)] and protein 
concentration was measured using the colorimetric BCA protein assay kit (Pierce 
Chemical). 200 and 400 µg of proteins were incubated with 200µl of the fluorogenic 
substrate, 4-methylumbelliferyl-β-D-glucuronide  (2mM, Sigma-Aldrich, Milan, Italy), 
for 0.5 and 1 h at 37 °C. The reaction was stopped by adding 200µl of the carbonate 
stop buffer (0.5 M NaHCO3/0.5 M Na2CO3, pH 10.7), and the fluorescence of the 4-
methylumbelliferone liberated was measured in a fluorimeter (GloMax-Multi Detection 
System; Promega) using 365nm excitation and 460nm emission. Absolute fluorescence 
of wild-type RCS was used as control. GusbKO clones as well as WT RCS cells were 
kept in medium containing 2mg/ml chondroitin sulphate (Sigma Aldrich) for 48h before 
any experiment.  
Co-Immunoprecipitation experiment.  
For co-immunoprecipitation experiments, whole-cell extracts were prepared in 0.3% 
Chaps-containing lysis buffer (40 mM HEPES, pH 7.4, 120 mM NaCl, 1 mM EDTA, 
50 mM NaF, 1.5 mM Na3VO4, 10 mM β-glycerophosphate, 0.3% Chaps, and EDTA-
free protease inhibitors) as described in a previous report (Kim et al., 2002), and 
immunoprecipitated with anti-UVRAG antibody (MBL). Precipitated proteins were 
washed five times with 0.3% Chaps lysis buffer, separated by SDS–PAGE and 
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transferred onto membranes, were probed with antibodies against P-Uvrag S498 (gift 
from DH. Kim), Beclin-1 (CST), UVRAG (MBL), Rubicon (CST), Vps16 (SantaCruz). 
 Procollagen secretion assay.  
Synchronized procollagen type II (PC2) secretion was obtained  after incubating 
chondrocytes for 3 h at 40 °C to block PC2 in the ER, and then shifting the temperature 
to 32 °C (ER block release) for 15 min. Cells were then fixed in 4%PFA for 10’ at room 
temperature and then processed for immunofluorescence. Cells were incubated 1h with 
primary antibodies against PC2 (Ibridoma Bank) and Giantin (Abcam).    
 
Proteasome assay.  
RCS cells were amino acid starved for 50 minutes then stimulated for 6h with 3X amino 
acid mix. Proteasome activity was measured in 10µg of cell lysates with a Proteasome 
Activity Assay Kit (Abcam). The fluorogenic substrate Succ-LLVY-AMC was used to 
measure the chymotrypsin-like proteasome activity. Assays were carried out in a 100µl 
reaction volume according to the manufacturer’s instructions. Fluorescence was 
measured with a microtiter plate reader (GloMax-Multi Detection System; Promega) in 
the presence/absence of MG-132 after 20 min at 37°C for 30 min. The MG132-sensitive 
increase of fluorescence at 350/440 nm was considered as proteasomal activity and was 
expressed as relative fluorescence units (RFU). 
Long-lived protein degradation assay.  
RCS cells were seeded in 6 well/plate at 2.5x105 cells/well. Intracellular proteins were 
labeled for 18 h at 37°C with 5 µCi/ml of L-[3H]serine (Perkin Elmer) in complete 
medium. Any unincorporated radioactivity was eliminated by rinsing the cells  3 times 
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with PBS. The cells were then incubated with fresh complete medium, and 2 mM 
 serine for 2h to degrade short-lived proteins. Next, the medium was removed by 
aspiration and replaced. This first time point (Time 0h) was harvested: the cells were 
washed twice with cold 10% TCA (w/v), plus 2 mM serine, to make sure that no 
radioactivity has remained adsorbed to the denatured proteins. The cell pellet was then 
dissolved at 37°C in 0.2 M NaOH for 2 h. The remaining wells were then incubated in 
fresh complete medium supplemented with 2 mM serine and 100nM MG-132 or 
DMSO, and incubated for 48h. The rate of degradation of long-lived proteins was 
calculated from the ratio 48h/0h of the acid-precipitable cell fraction. Plotting these 
values versus time gave the total rates of proteolysis.  
Tat–beclin-1 peptide treatment. 
In vivo. Newborn mice were intraperitoneally injected daily with Tat–beclin-1 peptide 
at 2 mg/kg resuspended in PBS. Control mice were injected with vehicle only. Mice 
were killed after 6 or 15 days, as specified in figure legends. In vitro. For peptide 
treatment, cells were washed with PBS(−) and treated with peptides (20µM, 2h) 
dissolved in OPTI-MEM (Gibco) acidified with 0.15% (v/v) 6N HCl. 
Chemicals.  
Tat-beclin-1 peptide (20µM) (Beclin-1 Activator II, retro-inverso Tat-beclin-1, 
Millipore). Tat-beclin-1-mutated (L17S) (20µM) was a gift from B. Levine. 
BafilomycinA1 (200nM) (Sigma), Torin-1 (1µM) (CST), MG132 (10µM) (Sigma), 
SAR405 (10µM) (Sigma). Protein G Sepharose (GE Healthcare). 
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Statistics.  
Paired Student’s t-test was performed when comparing the same cell population with 
two different treatments. Unpaired Student’s t-test was performed when comparing two 
groups of mice or different primary chondrocyte preparations. One-way ANOVA and 
Tukey’s post-hoc tests were performed when comparing more than two groups relative 
to a single factor (treatment or genotype).  
  
! 52!
 
 
 
 
 
 
 
 
 
 
Results 
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1. Pathogenic mechanism for dysfunctional autophagy in LSD cells. 
 
1.1 Defective autophagosome-lysosome fusion and collagen trafficking in MPS 
chondrocytes. 
 
To investigate if autophagy dysfunction in MPSs chondrocytes plays a role in the 
pathogenesis of bone growth retardation we analyzed autophagy in primary 
chondrocytes isolated from a mouse model of Mucopolysaccharidosis type VII 
(MPSVII)[47], which is caused by mutations in the b-glucuronidase gene (referred as 
Gusb-/- chondrocytes). In addition a cellular model of Rat Chondrosarcoma cell line 
(RCS)[60] knock-out for Gusb (referred as GusbKO) was created using Crispr/Cas9 
genome editing (Figure 10).  
 
 
Figure 10. Characterization of Crispr/Cas9 GusbKO RCS clones.  
A, schematic representation of the genetic mutation found in the GusbKO clone: a single base 
insertion within the first exon causes a frameshift and a premature stop codon within the second 
exon of the protein.  B, the resulted truncated protein lacks enzymatic activity. Bar graph 
displaying β-glucuronidase enzymatic activity. 
 
Gusb-/- chondrocytes showed swollen lysosomes (Lys), monitored by electron 
microscopy and accumulation of the lysosomal marker LAMP-1 (Figure 11A). 
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Figure 11. A block of autophagy in MPS cells.  
A, Lamp-1 Immuno-EM from primary cultured chondrocytes isolated from Gusb+/+ and Gusb-/- 
mice.  Scale bar, 500nm. Red line indicates lysosomes. B, Western blot analysis of Lamp-1, 
SQSTM1/p62 and LC3 II accumulation in primary cultured chondrocytes with the indicated 
genotypes. β-Actin was used as a loading control. Blot is representative of 3 independent 
experiments. C, Bar graphs show protein levels of the indicated protein (normalized to β-Actin) 
in Gusb-/- chondrocytes and expressed as fold increase compared to control (Gusb+/+). Values 
are expressed as mean (±s.e.m.) of n = 3 independent chondrocyte preparations (Student’s t-test, 
* p≤ 0.05, ** p≤ 0.005). 
 
 
Damaged organelles result to be filled with undigested substrates, as demonstrated by 
SQSTM1/p62 receptor accumulation (Figure 11B-C). Gusb-/- cells had higher number 
of autophagosomes (AVs) compared to their correspondent control, as monitored by 
quantifying the conversion of LC3I to the autophagosome–associated lipidated form 
(LC3II) (Figure 11B-C) and by MAP1LC3 immunofluorescence analysis (Figure 12A-
B). 
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To test if the accumulation of AVs was due to an enhanced rate of AV biogenesis we 
performed two assays: an immunofluorescence to detect WIPI-2 puncta formation 
(Figure 12A-B) and a time course analysis of LC3-I to -II lipidation in presence of the 
lysosomal inhibitor Bafilomycin A1 (Baf.A1) (Figure 12C-D). WIPI-2 is an early 
autophagosomal marker: it is recruited to form autophagosomes before and during LC3 
lipidation and it disassociates before the autophagosome matures[61]. Baf.A1 is a 
lysosomal inhibitor used to measure autophagic flux by preventing AV degradation 
within the Lys[62]. The rate of AV formation during the time course of inhibition is 
calculated using the ratio of AV accumulation between 3h and 1h of treatment.  
 
 
Figure 12. Normal autophagosome biogenesis in Gusb-/- primary chondrocytes. 
A, Immunofluorescence of WIPI-2 and LC3 in primary chondrocytes with the indicated 
genotypes, after 24h amino acid treatment. B, bar graph displaying quantization of WIPI-2 and 
LC3 puncta per cell (Student’s t-test, *** p≤0.0005). N ≥ 40. C, Western blot analysis of LC3II 
accumulation in the presence of the lysosomal inhibitor Bafilomycin A1 (200nm) for the 
indicated time points. D, bar graph displaying the rate of autophagosome formation in the 
presence of Baf. A1 (the rate is calculated using the ratio of accumulated LC3 II between 3h and 
1h of treatment). N = 3 independent experiments. 
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As shown in Figure 12, both of these assays display normal AV biogenesis in Gusb-/- 
when compared to control cells.  
The accumulation of AV was rather the consequence of a failure to properly complete 
the late stage of the autophagic process that is a defective AV digestion by Lys[53]. By 
performing a triple immunofluorescence for Lamp-1, LC3 and SQSTM1/p62 in primary 
chondrocytes, we observed a defective AV-Lys co-localization and accumulation of the 
SQSTM1/p62 autophagy substrate in MPS compared to control chondrocytes (Figure 
13A-C). 
 
 
 
Figure 13. See page 57 for figure legend. 
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Figure 13. Impaired autophagosome-lysosome fusion in MPS cells.  
A, Immunofluorescence of Lamp-1, SQSTM1/p62 and LC3 in primary chondrocytes isolated 
from mice with the indicated genotypes. The insets show higher magnification, single color 
channels, Lamp-1-p62 and Lamp-1-LC3 co-localization of the boxed area. Scale bar, 10µm. B, 
Bar graph displays quantification of Lamp-1 co-localization with LC3 and p62. Data are 
Mander’s coefficient means (±s.e.m.) of 3 independent experiments (Student’s t-test *p<0.05). 
C, Bar graph displays quantification of SQSTM1/p62 puncta per cell. Data are means (±s.e.m.) 
of 3 independent experiments (Student’s t-test ***p<0.0005). 
 
In addition, the co-localization between SQSTM1/p62 and lysosomes was found 
impaired, suggesting an improper cargo delivery to lysosomes (Figure 13A-B). As 
shown in Figure 14, these finding were extended to the GusbKO cells for which we 
found the same results. 
 
 
Figure 14. Block of autophagy in GusbKO RCS cell line. 
A, Lamp-1 Immuno-EM from control (Ctr) and GusbKO RCS cells. Scale bar, 500nm. Bar 
graph displays the lysosome size (Student’s t-test, *** p<0.0005). B, Western blot analysis of 
Lamp-1 and LC3 II accumulation in control and GusbKO RCS cells. β-Actin was used as a 
loading control. Blot is representative of 3 independent experiments. C, immunofluorescence of 
Lamp-1, SQSTM1/p62 and LC3 in control and GusbKO RCS cells. Scale bar, 10µm. D, Bar 
graph displays quantification of Lamp-1 co-localization with LC3 and p62. Data are Mander’s 
coefficient means (±s.e.m.) of 3 independent experiments (Student’s t-test **p<0.005, *p<0.05). 
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We also analyzed the rate of fusion between lysosomes and autophagosomes using a 
tandem fluorescent-tagged autophagosomal marker in which LC3 was engineered with 
both monomeric red fluorescent protein (mRFP) and GFP. In this assay the GFP 
fluorescence loss is a direct measurement of autophagosome fusion because of GFP 
quenching by lysosomal acidic pH[63]. The validity of this analysis is not affected by 
the decreased degradation capability of lysosomes in the LSD models analyzed, as the 
green fluorescence is rapidly quenched by protonation occurring in the acidic lysosomal 
lumen. Specifically, control and GusbKO cells were transfected with the mRFP-GFP-
LC3 construct, and the autophagosome maturation was followed over a 48h period. The 
rate of autophagosome maturation, measured with the number of RFP-only 
puncta/autolysosomes, was markedly lower in GusbKO cells compared to that of 
control cells (Figure 15A-B and later on Figure 30 for primary Gusb-/- 
chondrocytes).  
 
Figure 15. Impaired autolysosome formation in GusbKO cells. 
A, RFP-GFP-LC3 was transiently expressed in control and GusbKO RCS cells. LC3 was 
monitored by fluorescence microscope two days post transfection. Scale bar, 10µm. B, bar 
graph displays quantitative analysis of RFP-only puncta (autolysosome) per cell (Student’s t-
test **p<0.005). 
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Previous work from our lab demonstrates that during bone growth autophagy plays a 
pivotal role in collagen trafficking and secretion[30]. In particular, has been shown that 
autophagy is induced in growth-plate chondrocytes during post-natal development and 
regulates the secretion of type II collagen (Col2), the major component of cartilage 
ECM. Mice lacking autophagy in chondrocytes experience endoplasmic reticulum (ER) 
storage of type II procollagen (PC2) and defective formation of the Col2 fibrillary 
network in the ECM. To investigate whether the autophagy dysfunction found in our 
cell models affects procollagen homeostasis in chondrocytes, we performed a 
procollagen trafficking assay in primary chondrocytes derived from Gusb+/+ and Gusb-/- 
mice. The trafficking test is achieved by exposing cells to shift temperature 
experiments. The incubation at 40°C blocks the procollagen in the ER and the 
subsequent shift at 32°C for 15 min allows the secretion wave to move towards the 
Golgi. Consistent with an impaired autophagy, we observed defective type II 
procollagen (PC2) trafficking in Gusb-/- chondrocytes compared to control cells (Figure 
16A-B). In particular, the trafficking was not abolished but significantly delayed.  
 
Figure 16. See page 60 for figure legend. 
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Figure 16. Delayed procollagen type 2 (PC2) trafficking in Gusb-/- chondrocytes. 
A, Giantin and PC2 immunostaining in Gusb+/+ and Gusb-/- chondrocytes. Synchronized PC2 
secretion was obtained  after incubating chondrocytes for 3 h at 40 °C to block PC2 in the ER, 
and then shifting the temperature to 32 °C (ER block release) for 15 min. B, Bar graph 
displaying quantification of Giantin-PC2 co-localization. The data are Mander’s Coefficient 
means (±s.e.m.) representative of 2 independent experiments, n > 90 cells were analyzed for 
each experiment and time point. Scale bar, 10µm (Student’s t-test, *** p<0.0005). 
 
 
1.2 Enhanced mTORC1 signaling in LSD chondrocytes. 
 
Lysosome is emerging as critical regulator of mTORC1 signaling. Pharmacological 
inhibition of lysosome impairs mTORC1 activation in response to amino acids in 
different cell types[25]. However, a similar inhibition in chondrocytes has been recently 
reported to have an opposite effects on mTORC1 signaling, suggesting that 
chondrocytes may respond differently than other cells to the lysosomal impairment[64]. 
To assess the status of mTORC1 activity in case of LSD we took advantage of different 
cellular models: primary chondrocytes isolated from mouse models of MPSVII (Gusb-/-) 
and MPSVI (Arsb-/-)[48], mesenchymal-derived chondrocytes isolated from three MPSI 
human patients[65] and GusbKO RCS cells.  
As discussed in the introduction, the mTORC1 kinase is known to be responsive to 
most of the stimuli a cell can encounter. The pathway that connects growth factors to 
mTORC1 has been extensively characterized and is activated when insulin and other 
ligands/growth factors bind their tyrosine kinase receptors at the plasma membrane. 
This initiates a series of intracellular phosphorylation-cascades that ultimately lead to 
the inactivation of the multiple mTORC1 inhibitors (see introduction), thus enhancing 
the activity of the complex. 
To measure the activity of the mTORC1 complex in our cell lines we performed a 
stimulation with a cocktail of growth factors. Cells were starved for fetal bovine serum 
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(FBS) for 50 minutes and then stimulated for different time points with 10% FBS. 
mTORC1 activation was monitored by analyzing the phosphorylation of two known 
substrates: S6K on threonine 389 (T-389) and ULK1 on serine 757 (S-757). As shown 
in Figure 17, both Gusb-/- and control cells display the same activation kinetics during 
the time course stimulation. 
 
Figure 17. Normal mTORC1 response after growth factors stimulation.  
A, Western blot analysis of mTORC1 signaling in primary chondrocytes isolated from mice 
with the indicated genotype and stimulated with 10% Fetal Bovine Serum (FBS) for the 
indicated hours (h). (B) Bar graphs showing phosphorylation levels of the indicated protein 
(normalized to their total levels) in Gusb-/- chondrocytes and expressed as fold increase 
compared to control (Gusb+/+; dotted line). Values are expressed as mean (±s.e.m.) of n = 2 
independent chondrocyte preparations. 
 
Given the peculiar contribution of amino acids to the regulation of mTORC1 (see 
introduction) and since they act independently of the insulin/PI3K pathway, relying 
most on nutrients derived from functional lysosome and proteasome activities, we plan 
to analyze the response of cells with impaired lysosomal function to this particular 
source of energy.  
MPS cells were kept in culture with normal growth medium until they where subjected 
to an amino acids deprivation/stimulation time course. Cells were starved for 50 
minutes in a medium containing everything but amino acids, then were subjected to 
refeeding with an excess of amino acids for different time points. As shown in Figure 
18, Gusb-/- primary chondrocytes showed enhanced and sustained mTORC1 signaling 
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both at steady state (Figure 18A) and in response to amino acid stimulation (Figure 
18B-C) compared to their correspondent controls. 
 
 
Figure 18. Enhanced mTORC1 signaling in Gusb-/- chondrocytes. 
A-C, Phosphorylation levels of mTORC1 substrates (ULK and S6K1) in primary chondrocytes 
isolated from Gusb+/+ and Gusb-/- mice (A) at steady state and (B) stimulated with amino acid 
(A.A) for the indicated time (h=hour). C, Bar graphs show phosphorylation levels of the 
indicated protein (normalized to their total levels) in Gusb-/- chondrocytes and expressed as fold 
increase compared to control (Gusb+/+; dotted line). Values are expressed as mean (±s.e.m.) of n 
= 4 independent chondrocyte preparations (Student’s t-test, * p≤ 0.05). 
 
These abnormal responses to amino acid stimulation were further confirmed in the other 
LSD cell lines analyzed, as shown in Figure 19. 
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Figure 19. Enhanced mTORC1 signaling in LSD cells.  
A-C, Western blot analysis of mTORC1 signaling upon a time course of amino acid 
stimulation. Bar graphs display phosphorylation levels of the indicated protein 
(normalized to their total levels and expressed as fold increase vs each relative control) 
in (A) GusbKO RCS cells, (B) Idua-/- differentiated human mesenchimal stem cells and 
(C) Arsb-/- mouse primary chondrocytes expressed as fold increase compared to their 
corresponding control. N = 3 independent experiments (Student’s t-test *p<0.05, 
**p<0.005).  Arrow head in A indicates the specific band for S6K. 
 
Amino acids activate mTORC1 by inducing its association to the lysosomal membrane, 
where the main mTORC1 activator Rheb resides[21]. To further analyze this 
phenomenon and to verify that the enhanced activity was coupled with a higher 
association to lysosomes, a co-immunofluorescence was performed. Consistently, the 
association of mTOR to lysosomes (revealed by the co-localization between mTOR and 
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the lysosomal marker Lamp-1) was found significantly increased in Gusb-/- (Figure 
20A-B) and Arsb-/- (Figure 21A-B) chondrocytes compared to controls when subjected 
to the same starvation/stimulation experiments as in Figures 18 and 19.  
 
Figure 20. Enhanced mTORC1 association to lysosome in Gusb-/- primary chondrocytes. 
A, Primary chondrocytes were starved for amino acids for 50 min and then amino acids were 
added for the indicated time points. Cells were then processed in an immunofluorescence assay 
to detect mTOR (green)-Lamp-1 (red) colocalization. Cell were co-stained with 4′,6′-diamidino-
2- phenylindole (DAPI) for DNA content (blue), and imaged. The insets show higher 
magnification and single color channels of the boxed area. Scale bar, 10 µm. B, Bar graph 
displays co-localization analysis (mTOR positive pixels in Lamp-1 regions) in Gusb-/- expressed 
as fold increase compared to control (Gusb+/+). Data are expressed as mean  (±s.e.m) of n=3 
independent experiments (Student’s t-test, ** p≤ 0.005). 
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Figure 21. Enhanced mTORC1 association to lysosome in Arsb-/- primary chondrocytes. 
A, Arsb-/- chondrocytes were starved for amino acids for 50 min or starved and then re- 
stimulated with amino acids for the indicated times. Cells were then processed in an 
immunofluorescence assay to detect mTOR, Lamp-1, co-stained with DAPI for DNA content, 
and imaged. The insets show higher magnification and single color channels of the boxed area. 
Scale bar, 10µm. B,  Bar graphs display quantitative analysis of co-localization, data are 
expressed as mean (±s.e.m) of n=3 independent experiments (Student’s t-test, * p<0.05, ** 
p<0.005, *** p<0.0005). 
 
This suggests that an altered insulin/growth factor signaling pathway was not the main 
cause of mTORC1 hyperactivity in MPS cells and that in particular the signaling arising 
from amino acids (lysosomal and/or proteasomal) was the major cause of the observed 
phenotype. 
Literature data so far suggests that an impaired lysosomal function would impair the 
mTORC1 signaling, probably because it hampers the capability to pump amino acids to 
the complex. We hypothesized that this phenomenon might be true if restricted to the 
acute inhibition (hours) of lysosomal function achieved by drugs, since our data were 
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suggesting that the chronic inhibition of lysosomal function enhances rather than 
inhibits mTORC1 signaling in MPS chondrocytes.  
Surprisingly, mTORC1 signaling was not enhanced in fibroblasts isolated from MPSVII 
mice (Figure 22) and in MPSVI HeLa cell line (ArsbKO)(Figure 23), generated by 
Crisp/Cas9 mediated genome editing, compared to their respective control cells.  
 
Figure 22. mTORC1 signaling in MPS fibroblast. 
A, Phosphorylation levels of mTORC1 substrates (ULK1 and S6K1) in primary fibroblasts 
isolated from Gusb+/+ and Gusb-/- mice upon 2h A.A. stimulation. B, Bar graphs display 
phosphorylation levels of the indicated protein (normalized to their total levels). The data are 
representative of 2 independent experiments. 
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Figure 23. mTORC1 signaling in ArsbKO HeLa cell line. 
A, schematic representation of genetic mutation found in the ArsbKO Hela clone: a deletion of 
55 base pairs within the first exon causes a frameshift and a premature stop codon.  B, Western 
blot displaying absence of the Arsb protein. β-Actin was used as a loading control. C, 
Phosphorylation levels of mTORC1 substrates (ULK and S6K1) in ArsbKO and Ctr stimulated 
with amino acid (A.A) for the indicated time points. D, Bar graphs show phosphorylation levels 
of the indicated protein (normalized to their total levels) in ArsbKO and expressed as fold 
increase compared to controls. Values are expressed as mean (±s.e.m.) of n = 3 independent 
experiments 
 
 
1.3 Proteasomal regulation of mTORC1 
We hypothesized that lysosomal storage triggers a chondrocyte-specific response that 
enhances mTORC1 signaling. A cross talk between lysosomes and proteasomes, the 
two main degradative station of the cell, exists. Furthermore, the amino acids derived 
from proteasome-mediated proteolysis can induce mTORC1 signaling. To assess the 
contribution of proteasome to the increased mTORC1 signaling a series of experiments 
were performed. By using a luminescent Suc-LLVY peptide, susceptible to the 
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chymotrypsin-like activity of the proteasome, we measured the luminescent signal 
resulting from its cleavage in control and GusbKO RCS cells. We observed a 
significantly higher proteasome activity in GusbKO compared to control chondrocytes 
(Figure 24A).  
 
 
 
Figure 24. Enhanced proteasome activity in MPS cells. 
A, Luminescent signal resulting from the cleavage of a luminescent Suc-LLVY peptide by the 
chymotrypsin-like activity of the proteasome was measured in control and GusbKO RCS cells. 
Data are representative of 3 independent experiments and are graphed as relative fluorescence 
units (RFU) (Student’s t-test, * p≤ 0.05). B, Control and GusbKO RCS cells were pulse labeled 
for 18h with 3H-Ser and chased for 48h in medium containing vehicle or 100nM Mg-132. The 
rate of protein degradation was measured as the difference of initially incorporated radioactivity 
relative to that remaining at the end of the chase period. Values are expressed as mean (±s.e.m.) 
of n = 3 independent experiments (Student’s t-test, * p≤ 0.05, ** p≤ 0.005). 
 
Then, we decided to measure the overall rate of protein degradation. Control and 
GusbKO RCS cells were pulse labeled for 18h with 3H-Ser, in order to labeled long-
lived proteins, and chased for 48h in cold medium. The rate of protein degradation was 
measured as the difference of initially incorporated radioactivity relative to that 
remaining at the end of the chase period. In spite of a lysosomal damage, proteolysis 
rate was found significantly increased in GusbKO compared to controls (Figure 24B). 
To determine to what extent proteasome contributes to this increased proteolysis, the 
chased period was performed in the presence of the proteasome inhibitor MG-132. As 
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shown in Figure 24B, the fraction of amino acids generated by the proteasome (MG132-
sensitive) was increased in GusbKO chondrocytes compared to controls. We reasoned 
that the higher proteasomal proteolysis, by generating an excess of amino acids, was the 
driving force for the increased mTORC1 signaling found in our cellular models. In this 
scenario, a similar MG132-sensitive mTORC1 signaling would be expected.  We 
observed that treatment with MG132 (Figure 25A-B), but not with lysosomal inhibitors 
(E64-d) (Figure 25C-D), normalized mTORC1 signaling in GusbKO chondrocytes. 
 
Figure 25. mTORC1 signaling is proteasome-sensitive in MPS cells. 
A, Western blot analysis of mTORC1 signaling in control (Ctr) and GusbKO RCS cells treated 
with Mg-132 (10µM) or DMSO (-) in the presence of A.A. for 6h. Arrowhead indicate specific 
band. B, Bar graphs show phosphorylation levels of the indicated protein (normalized to their 
total levels) in GusbKO chondrocytes expressed as fold increase compared to control cells. 
Values are expressed as mean (±s.e.m.) of n = 3 independent experiments (Student’s t-test, * p≤ 
0.05, ** p≤0.005). C, Western blot analysis of mTORC1 signaling in control (Ctr) and GusbKO 
RCS cells pre-treated for 16h with E64-d (20µg/ml) or vehicle (-) and then stimulated with A.A. 
for 6h. D, Bar graphs show phosphorylation levels of the indicated protein (normalized to their 
total levels) in GusbKO chondrocytes expressed as fold increase compared to control cells. 
Values are expressed as mean (±s.e.m.) of n = 2 independent experiments.  
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These data confirm that an enhanced mTORC1 signaling in MPS chondrocytes is 
mediated by an increased proteasomal proteolysis. Notably, proteasome activity was not 
enhanced in MPSVII fibroblasts and in ArsbKO cell compared to their respective 
control cells (Figure 26) and consistently in these cells mTORC1 signaling was not 
induced compared to controls (See Figures 22 and 23).   
 
 
Figure 26. Proteasome activity in non-chondrocyte MPS cells. 
A-B, Luminescent signal resulting from the cleavage of a luminescent Suc-LLVY peptide by 
the chymotrypsin-like activity of the proteasome was measured in control and GusbKO RCS 
cells (A), or control and ArsbKO Hela cells (B). Data are representative of 3 independent 
experiments and are graphed as relative fluorescence units (RFU) (Student’s t-test, * p≤ 0.05). 
 
This phenotype seems to be the consequence of an enhanced proteasome activity that, 
by increasing cellular amino acid levels, sustains mTORC1 signaling. The mechanism 
by which lysosome inhibition led to the increased proteasome activity is currently 
unclear and it is beyond the aim of this thesis.   Recent data indicated that proteasome 
turnover is mediated by lysosomes[66]. One possibility could be that lysosome 
dysfunction by impairing proteasome turnover raises its intracellular level and in turn 
enhances its total activity [67]. In any case, these observations suggest the existence of 
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additional, still uncharacterized, pathways through which the lysosome may indirectly 
regulate mTORC1 signaling. 
 
1.4 mTORC1 inhibits autophagosome-lysosome fusion in MPS chondrocytes via 
UVRAG. 
 
To verify whether the enhanced mTORC1 signaling contributed to the inhibition of 
autophagy in MPS chondrocytes, we genetically reduced the amount of mTOR by 
generating a mouse line lacking one allele of the mTORC1 scaffold subunit Raptor[68]. 
Heterozygous Raptor (Rpt) mice[69] were then backcrossed with heterozygous Gusb 
mice in order to obtain double Gusb-/-;Rpt+/- mice. As expected, primary chondrocytes 
isolated from these mice showed almost 50% reduction in the amount of Raptor protein 
(Figure 27). 
 
Figure 27. Normalization of mTORC1 signaling restores autophagy flux in MPS 
chondrocytes. 
A, Western blot analysis of LC3I/II, SQSTM1/p62 and Raptor in chondrocytes isolated from 
mice with the indicated genotypes. β-Actin was used as a loading control. Blot is representative 
of 3 independent experiments. B, Bar graph shows quantification of protein amount normalized 
to β-actin and relative to Gusb-/- (ANOVA, P=0.0064 ; Tukey’s post-hoc test, ** p≤0.005, * 
p≤0.05). 
 
Strikingly, Gusb-/-;Rpt+/- primary chondrocytes showed reduced accumulation of LC3II 
and of SQSTM1/p62 compared to Gusb-/- chondrocytes (Figure 27). 
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The subsequent reduction in mTORC1 signaling was tested by subjecting cells to amino 
acids starvation/stimulation time course. Figure 28 shows normalization of mTORC1 
signaling in Gusb-/-;Rpt+/- cells.  
 
Figure 28. Normalization of mTORC1 signaling in MPS chondrocytes. 
A, Western blot analysis of mTORC1 signaling in primary cultured chondrocytes isolated from 
Gusb-/- and Gusb-/-;Rpt+/- mice upon a time course of  amino acid stimulation. B, Bar graphs 
show phosphorylation levels of indicated proteins (normalized to their total levels) after 24h of 
amino acids (A.A.) stimulation. Values were expressed as fold increase compared to Gusb-/- 
(ANOVA, P=0.009; Tukey’s post-hoc test, *p<0.05). 
 
The rescue found in autophagy substrates was most likely the consequence of a 
restoration of the autophagy flux, as demonstrated by enhanced AV-Lys co-localization 
and increased SQSTM1/p62 delivery to lysosomes in Gusb-/-;Rpt+/- compared to Gusb-/- 
chondrocytes (Figure 29).  
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Figure 29. Normalization of mTORC1 signaling restores autophagosome-lysosome fusion in 
MPS chondrocytes. 
A, Immunofluorescence of Lamp-1, p62 and LC3 in primary chondrocytes isolated from mice 
with the indicated genotypes. The insets show higher magnification, single color channels, 
Lamp-1-p62 and Lamp-1-LC3 co-localization of the boxed area. Scale bar, 10 µm. B, 
quantification of Lamp-1 co-localization with LC3 and p62. Data are Mander’s coefficient 
means (±s.e.m.)(ImageJ plug-in). ANOVA Lamp-1-LC3 P=7.39E-06, Lamp1-p62 P=0.008; 
Tukey’s post-hoc test, *p≤0.05; *** p≤0.0005. C, quantification of p62 puncta of cells shown in 
A (ANOVA P=4.67E-05; Tukey’s post-hoc test *** p≤0.005, *p≤0.05). 
 
Restoration of proper AV-Lys was also demonstrated by transiently transfecting the 
tandem GFP-RFP-LC3 in primary chondrocytes from Gusb-/-, Gusb-/-;Rpt+/- and controls 
(Figure 30).  
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Figure 30. Autolysosome formation assay. 
A, Tandem RFP-GFP-LC3 protein was transiently expressed in primary chondrocytes with the 
indicated genotypes. LC3 was monitored by fluorescence microscope two days post-
transfection and after 24h amino acid treatment. Scale bar, 10µm.  B-C, Quantitative analysis of 
GFP+/RFP+ puncta (autophagosome, yellow) (B) and GFP-/RFP+ puncta (autolysosome, red) 
(C). Mean value of 3 independent experiments is shown as a horizontal bar (ANOVA, GFP 
puncta P=0.002, RFP puncta P=1.63E-06; Tukey’s post-hoc test, **p≤0.0005, ***p≤0.0005). 
 
As expected, the lysosome phenotype was not rescued in Gusb-/-;Rpt+/- compared to 
Gusb-/- chondrocytes (Figure 31).  
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Figure 31. Lysosomal phenotype in MPS cells. 
Lamp-1 Immuno-EM from primary chondrocytes isolated from mice with the indicated 
genotype.  Scale bar, 500nm. 
 
Notably, restoring mTORC1 signaling to normal levels did not alter AV biogenesis as 
measured by time course analysis of LC3-I to -II lipidation in the presence of the 
lysosomal inhibitor Bafilomycin A1 (Figure 32A-B), suggesting that an enhanced 
mTORC1 signaling directly impact the rate of AV-Lys fusion. Moreover, the nuclear 
translocation of the pro-autophagy transcription factors TFEB and TFE3 was similar 
between Gusb-/-;Rpt+/- and Gusb-/- chondrocytes (Figure 32C-D), suggesting that the 
normalization of mTORC1 signaling did not restore autophagy flux in MPS 
chondrocytes via TFEB/TFE3 nuclear translocation. 
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Figure 32. Normal autophagosome biogenesis in Gusb-/-;Rpt+/- primary chondrocytes. 
A, Western blot analysis of LC3II accumulation in the presence of the lysosomal inhibitor 
Bafilomycin A1 (200nm) for the indicated time points. Bar graphs display the rate of 
autophagosome formation calculated using the ratio of accumulated LC3 II between 3h and 1h 
of treatment. B, Immunofluorescence analysis of TFEB and TFE3 nuclear localization in 
primary chondrocytes with the indicated genotype after 50 minutes of amino acid starvation 
(STV) and upon 24h of amino acid stimulation (fed). Cells were co-stained with DAPI to define 
nuclear region. C, bar graphs display quantification of the percentage of cells positive for 
nuclear translocation. The data are representative of 3 independent experiments, n > 90 cells 
were analyzed for each time point. Scale bar, 10 µm  (Student’s t-test, * p≤0.05). 
 
Until two years ago it was described that the major mechanism by which mTORC1 
inhibits autophagy is by phosphorylating ULK1. It was shown that mTORC1 also 
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targets proteins other than ULK1, such as Atg13, Atg14L and AMBRA1. These 
mTORC1 targets are mainly known to function at early stages of autophagosome 
formation. Whether mTORC1 regulates autophagy at later stages, such as 
autophagosome maturation, remained unknown until it was demonstrated that, through 
phosphorylating UVRAG, mTORC1 was engaged in late stages of autophagy and 
endosome maturation, defining a broader range of mTORC1 functions in the 
membrane-associated processes[17]. Since we couldn’t detect any obvious effect of 
mTORC1 on early autophagy stages (see Figure 12), we hypothesized a contribution in 
the late stages, according to the overt fusion defect that has been observed. It is known 
that once mTORC1 phosphorylates UVRAG its affinity for the inhibitor partner 
Rubicon is enhanced. Thus, to analyze the status of this protein complex in GusbKO 
cells, we performed co-IP experiments. Figure 33A shows that GusbKO cells had higher 
levels of UVRAG S497 phosphorylation compared to control cells, and this 
phosphorylation was mTORC1-dependent since it was blunted by Torin-1 treatment. 
 
Figure 33. Enhanced UVRAG phosphorylation and Rubicon binding in MPS cells. 
A-B, UVRAG immunoprecipitation (IP) assay testing endogenous UVRAG phosphorylation 
(A) and interaction with Rubicon and Beclin1 (B) in control and GusbKO RCS chondrocytes. 
The increased UVRAG phosphorylation is blunted after treatment with the mTORC1 inhibitor 
Torin-1 (1µM; 6h). IgG: negative IP control. 
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Furthermore, we found an increased interaction between UVRAG and Rubicon in 
GusbKO compared to control cells (Figure 33B). However, we observed no differences 
in the interaction between UVRAG and Vps16 (a member of the HOPS complex) 
(Figure 34) between GusbKO and control chondrocytes, suggesting that the activity of 
the UVRAG/HOPS complex was not altered in LSD chondrocytes.  
 
Figure 34. UVRAG/HOPS complex in MPS chondrocytes.  
UVRAG immunoprecipitation assay testing endogenous UVRAG interaction with Vps16 and 
Beclin1 in control and GusbKO RCS chondrocytes. IgG: negative control. 
 
UVRAG is also part of the Vps34/Beclin1 complex, which produces a pool of PI(3)P on 
endo-lysosome membrane that promotes AV-Lys fusion[10]. It has been demonstrated 
that UVRAG phosphorylation suppresses the UVRAG-mediated stimulation of Vps34 
kinase activity, downregulating the amount of PI(3)P. As expected following a higher 
UVRAG phosphorylation, we observed a significant lower level of PI(3)P in GusbKO 
compared to control chondrocytes (Figure 35). 
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Figure 35. Impaired Vps34 kinase activity in MPS cells. 
A, Representative images of membrane-associated PtdIns(3)K assay in situ. RCS chondrocytes 
were transfected with  GFP-2xFYVE and treated with or without Tat-Beclin1 (10µM), Torin1 
(1µM) or co-transfected with myc-UVRAG, in the presence of A.A. for 6h. B, graph shows 
quantitative analysis of PI3P puncta formation. Mean value is shown as a horizontal bar. The 
error bars represent means (±s.e.m.) (ANOVA P<0.0001; Tukey’s post-hoc test, * p≤0.05, *** 
p≤0.0005; n > 20) Scale bar, 10 µm. 
 
The identification of this pathological mechanism allowed us to develop several 
therapeutic options. We were able to demonstrate that (i) mTORC1 inhibition with 
Torin-1 treatment (Figures 35-36), (ii) forced overexpression of UVRAG (Figures 35 
and 37) and (iii) enhancing Beclin-1 activity with Tat-Beclin-1 peptide (Figures 35 
and 38) restored PI(3)P levels and in turn restored autophagy in GusbKO and Gusb-/- 
chondrocytes, as demonstrated by enhanced AV-Lys fusion, decreased LC3II and 
SQSTM1/p62 protein accumulation (Figures 35-38).  
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Figure 36. Torin-1 treatment rescues the autophagy flux in MPS cells. 
A, Western blot analysis of P-ULK1, SQSTM1/p62 and LC3 in Gusb+/+ and Gusb-/- primary 
chondrocytes treated for 24h with Torin-1 (1µM) or vehicle alone (DMSO). β-Actin was used as 
a loading control. The blot is representative of 3 independent experiments. B, Bar graph 
displaying the reduction of SQSTM1/p62 and LC3 II levels after Torin-1 treatment. Data are 
means (±s.e.m.) of protein levels (normalized to β-actin) and expressed as fold increase relative 
to untreated Gusb+/+  (Student’s t-test * p<0.05). 
 
 
Figure 37. See page 81 for figure legend 
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Figure 37. UVRAG over-expression rescues autophagy flux in MPS cells. 
A, myc-UVRAG was transiently expressed in Gusb-/- primary chondrocytes. Myc expression, 
LC3 and SQSTM1/p62 were monitored by fluorescence microscope two days post-transfection. 
Scale bar, 10µm . B, Bar graph displaying quantitative analysis of SQSTM1/p62 and LC3 
puncta per cell. Mean value is shown as a horizontal bar. (Student’s t-test, *** p≤ 0.0005, n ≥ 
20 ). 
 
 
 
 
Figure 38. Tat-Beclin-1 treatment rescues autophagy flux in MPS cells 
A, Western blot analysis of LC3I/II and SQSTM1/p62 in control and GusbKO RCS cells treated 
with Tat-Beclin-1 (10µM; 2h) and an inactive form of Tat-Beclin-1 (Tat-Beclin-1-m). β-Actin 
was used as a loading control. The blot is representative of 3 independent experiments. B, Bar 
graphs display quantification of protein amount normalized to β-actin and relative to control 
(vehicle treated) cells (ANOVA, P62 P<0.0001, Tukey’s post-hoc test, ***p<0.0005, 
**p<0.005, *p<0.05). C, Immunofluorescence of Lamp-1 and LC3 in GusbKO cells treated 
with Tat-Beclin-1 peptide (10µM; 2h). The insets show a higher magnification  of co-
localization in selected areas. Scale bar, 10µm D, Quantification of Lamp-1-LC3 co-localization 
is shown as mean (±s.e.m.) of Mander’s Coefficients resulting from three independent 
experiments (Student’s t-test, *p<0.05). 
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Notably, the pharmacological inhibition of Vps34 with SAR405[70] in chondrocytes 
induced a LSD-like phenotype (accumulation of SQSTM1/p62 and of LC3II) (Figure 
39). All together these data suggest that mTORC1 inhibits AV-Lys fusion in MPS 
chondrocytes at least in part through the inhibition of UVRAG-Vps34-Beclin1 complex 
activity.  
 
 
Figure 39. SAR405 treatment in chondrocytes induced a LSD-like phenotype. 
A, western blot analysis of SQSTM1/p62 and LC3 in RCS cells treated with PIK3C3/Vps34 
inhibitor (SAR405, 10µM, 24h). Blot shows three independent replicates.  β-Actin was used as 
a loading control. B, bar graphs displaying proteins levels normalized to β-Actin. Values are 
expressed as mean (±s.e.m.) (Student’s t-test, * p<0.05; **p<0.005) 
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2. Genetic and pharmacological approaches to rescue mTORC1 
signaling in the skeleton of LSD mouse models. 
 
2.1 Genetic modulation of mTORC1 signaling. 
 
As reported in the introduction, linear growth is largely a function of endochondral bone 
elongation, a process that occurs mainly in the cartilaginous growth plate. The growth 
plate is divided into several distinct regions, each populated with chondrocytes 
displaying characteristic behaviors. For instance, the hypertrophic chondrocyte, simply 
through its size, is the principal engine of bone growth. Thus the morphological analysis 
of the growth plate gives key information about the healthiness of long bones.  
To analyze the long bone growth in LSD mice we performed both 
immunohystochemical analysis on growth plates and morphometric analysis of femur 
and tibia length. We performed immunohistochemistry of paraffin sections from 
Gusb+/+ and Gusb-/- mice at post-natal day 15. As shown in Figure 40A (panels i-ii) the 
normal architecture of the growth plate was affected in Gusb-/- compared to control. 
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Figure 40. Limitation of mTORC1 improved bone phenotype in MPSVII mice.  
A, Representative images of P15 femoral growth plates sections from Gusb+/+, Gusb-/- and 
Gusb-/-; Raptor+/- mice. Panels i-iii, staining with hematoxylin & eosin (H&E) shows the 
regions chosen for the analysis. Panels iv-xv, immunostaining with P-S6 (iv-vi), p62 (vii-ix), 
Coll X (x-xii) and Coll II (xiii-xv). Nuclei were counterstained with hematoxylin or DAPI 
(p62). n=5 mice per genotype. Scale bar (100 µm). B-C, Bar graphs displaying the length of 
hypertrophic zone measured according to Coll X staining (B; ANOVA, P=0.003; Tukey’s post-
hoc test, * p ≤ 0.05, ** p≤  0.005) and the amount of collagen (% of Gusb+/+) in the growth plate 
homogenates (C; ANOVA, P=0.003; Tukey’s post-hoc test, *  p ≤ 0.05, ** p≤  0.005). 
 
Ematoxilin and Eosin staining allows easy distinction between resting, proliferating and 
hypertrophic chondrocytes. Moreover Gusb-/- growth plates displayed accumulation of 
SQSTM1/p62 (Figure 40A; panels vii-viii) and significantly lower collagen type II and 
type X levels compared to the ones from littermate control mice (Figure 40A; panels x-
xii;xiii-xiv and Figure 40C), suggesting that the mTORC1 signaling and autophagy 
were altered in the cartilage of Gusb-/- mice and this in turn results in improper collagen 
secretion, confirming the pathogenic mechanism obtained by analyzing primary 
chondrocytes in vitro.  
Alteration of autophagy and reduction in collagen levels matched with an altered 
growth, thus Gusb-/- mice displayed shorter bones both at post-natal day 15 (P15) and 
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P30, as measured by morphometric analysis on alcian blue/alizarin red colored bones 
(Figure 41A-D).  
 
Figure 41. Limitation of mTORC1 improved bone growth in MPSVII mice 
A, Representative images of alcian blue/alizared red staining of femurs and tibia from P15 
Gusb+/+, Gusb-/- and Gusb-/-; Raptor+/- mice (n ≥ 6 mice per genotype). B, Bar graphs displaying 
femur and tibia lengths from mice with the indicated genotype, data are expressed as mean  
(±s.e.m) of n ≥ 6 mice per genotype (ANOVA, femur P=1.26E-05, tibia P=0.005; *p<0.05, 
**p<0.005, ***p<0.0005). C, Representative images of alcian blue/alizared red staining of 
femurs and tibias from P30 Gusb+/+, Gusb-/- and Gusb-/-; Raptor+/- mice (n ≥ 6 mice per 
genotype). D, Bar graphs displaying femur and tibia lengths from mice with the indicated 
genotype, data are expressed as mean  (±s.e.m) of n ≥ 6 mice per genotype (ANOVA, femur 
P=8.44E-07, tibia P=1.79E-07; **p<0.005, ***p<0.0005). 
 
Next we asked whether mTORC1 dysfunction played any role in the observed bone 
growth retardation. Limitation of mTORC1 signaling in vivo (Gusb-/-;Rpt+/-) reduced S6 
phosphorylation (Figure 40A, panels iv-vi), restored autophagy flux, as measured by 
reduced SQSTM1/p62 levels (Figure 40A, panels vii-ix) and thus significantly 
improved collagen levels in the growth plates of Gusb-/-;Rpt+/- compared to Gusb-/- mice 
(Figure 40A-B; panels x-xv). The improvement in collagen amount and ECM proper 
composition was further analyzed biochemically by analyzing the amount of collagen in 
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growth plate homogenates (Figure 40C), supporting the non-quantitative 
immunohystochemical technique. 
Most importantly, femurs and tibia isolated from Gusb-/-;Rpt+/- showed an almost 
complete rescued bone growth retardation when measured at both P15 and P30 (Figure 
41A-D). These data clearly demonstrate that mTORC1 dysfunction plays an important 
role in the pathogenesis of the skeletal phenotype in MPSVII mice. 
 
2.2 Pharmacological modulation of autophagy. 
 
Next we tested whether enhancing autophagy would also have beneficial effects for the 
MPS bone phenotype. The activity of Beclin 1, a key pro-autophagy protein, can be 
pharmacologically enhanced using the TAT-Beclin1 peptide. When administered in 
vivo, Tat-Beclin1 is able to activate autophagy in growth plate chondrocytes without 
showing any side effects. In vivo, daily injection of Tat-Beclin1 peptide enhanced AV-
Lys fusion and SQSTM1/p62 degradation in the growth plate of control (Gusb+/+;GFP-
LC3tg/+) mice expressing the fluorescent autophagy reporter GFP-LC3 protein (Figure 
42A-B). 
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Figure 42. Tat-Beclin-1 peptide promotes Av-Lys fusion in the growth plate of wild type mice. 
A, Representative images of GFP–LC3 puncta (autophagosomes) and Lamp-1 immunostaining 
in femoral growth plates from GFP–LC3tg/+ mice at P6 and P15. Tat–beclin-1 peptide was 
administered where indicated (2 mg kg-1, daily for 6 and 15 days). The insets show a higher 
magnification  of co-localization in selected areas. Scale bar, 10µm. Bar graphs display 
quantification of Lamp-1-LC3 co-localization. Values are Mander’s coefficients means 
(±s.e.m.) of n = 3 mice per group (Student’s t-test, **p<0.005). B, Western blot analysis of 
Lamp-1, SQSTM1/p62 and LC3 in femoral growth plates homogenates. Tat–beclin-1 peptide 
was administered where indicated (2 mg kg-1, daily for 6 days). Bar graph displays amount of 
proteins relative to β-Actin. N=3 vehicle and n=4 Tat-Beclin-1 injected mice. 
 
This beneficial effect was retained when Tat-Beclin1 was injected in Gusb-/- mice 
bearing the reporter GFP-LC3 protein (Gusb-/-;GFP-LC3tg/+) (Figure 43A-B). 
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Figure 43. Enhanced autophagy improves bone phenotype in MPS mice. 
A-B, Representative images of (A) GFP–LC3 puncta (autophagosomes), Lamp-1 and (B) 
SQSTM1/p62 immunostaining in femoral growth plates from Gusb-/-;GFP–LC3tg/+ mice at P6. 
Tat–beclin-1 peptide was administered where indicated (2 mg kg-1, daily for 6 days). The insets 
show a higher magnification  of co-localization in selected areas. Scale bar, 10µm.  Bar graph 
displays quantification of Lamp-1-LC3 co-localization. Values are Mander’s coefficients means 
(±s.e.m.) (ImageJ plug-in) of n = 3 mice per group (Student’s t-test, *p<0.05). 
 
Strikingly, Gusb-/- mice treated daily with Tat-Beclin1 showed increased collagen levels 
in femoral and tibia cartilages (Figure 44A-C) and increased femur and tibia length 
compared to untreated Gusb-/- mice at P15 (Figure 44D-E). 
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Figure 44. Enhanced autophagy improves bone growth in MPS mice. 
A, Representative images of P15 femoral growth plates sections from Gusb+/+, Gusb-/- and 
Gusb-/- Tat-Beclin-1 treated mice immunostained with Coll X and Coll II. Nuclei were 
counterstained with hematoxylin. N=3 mice per group. Scale bar (100μm). B, Bar graphs 
displaying the length of hypertrophic zone measured according to Coll X staining (ANOVA, 
P=0.002; Tukey’s post-hoc test, * p ≤ 0.05, ** p≤ 0.005). C, Quantitative measure of collagen 
levels in the growth plate homogenates isolated from mice with indicated genotypes.  Values 
are expressed as % relative to Gusb+/+ mice. (ANOVA, P=9.52E-05; Tukey’s post-hoc test, 
*p≤0.05, ***p<0.0005). D, Representative images of alcian blue/alizared red staining of femurs 
and tibias from P15 Gusb+/+, Gusb-/- and Gusb-/- Tat-Beclin-1 treated (2mg/kg daily for 15 days) 
mice (n ≥ 8 mice per group). E, Bar graphs displaying femur and tibia lengths from mice with 
the indicated genotype, data are expressed as mean  (±s.e.m) (ANOVA, femur P=2.22E-06, 
tibia P=0.0006; ***p<0.0005). F, Representative images of alcian blue/alizared red staining of 
femurs and tibias from P15 Arsb+/+, Arsb-/- and Arsb-/- Tat-Beclin-1 treated (2mg/kg daily for 15 
days) mice (n ≥ 6 mice per group). G, Bar graphs displaying femur and tibia lengths from mice 
with the indicated genotype, data are expressed as mean  (±s.e.m) (ANOVA, femur P=0.0008, 
tibia P=0.001; * p ≤ 0.05, ** p≤  0.005, ***p<0.0005).    
 
Similar results were obtained in a different LSD mouse model (MPSVI; Arsb-/-) (Figure 
44F-G), indicating that our findings may be also extended to other LSDs. 
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These data clearly point to autophagy dysfunction as a major contributor of the bone 
growth retardation in LSD mice.  
 
 
  
! 91!
 
 
 
 
 
 
 
 
 
 
 
Discussion 
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In the first part of my PhD I contributed to the identification of a novel pathogenic 
mechanism responsible for dysfunctional autophagy in lysosomal storage disorders, 
while in the second part of my PhD I used the knowledge derived from the previous 
work to develop therapeutic approaches for the treatment of bone growth retardation in 
LSDs mouse models. 
 
Lysosomal storage disorders are inherited diseases characterized by progressive 
intracellular accumulation of undigested macromolecules due to lysosomal dysfunction. 
This results in a complex phenotype with broad pathological manifestations. Most of 
LSDs are characterized by defective skeletal growth[71]. Despite this, the mechanism 
by which lysosomal storage affects the function of bone cells is still unknown and the 
efficacy of current therapies on the skeletal system is very limited[44]. In this work we 
have identified a novel pathway that contributes to the bone growth retardation in LSDs.  
Autophagy dysfunction is a general phenomenon occurring in many LSDs although the 
pathogenic mechanisms are still unclear[72]. To date, the driving hypothesis is that the 
impairment of lysosomal degradation would impair the subsequent degradation of 
autophagosome, thus delaying the autophagic flux. However, our data point to 
mTORC1 and autophagy as main downstream effectors through which lysosomal 
storage affects chondrocyte functions. mTORC1 is a protein-signaling complex at the 
fulcrum of anabolic and catabolic processes, which acts depending on wide-ranging 
environmental cues[8]. It is generally accepted that lysosomes facilitate mTORC1 
activation by generating an internal pool of amino acids. Amino acids activate 
mTORC1 by stimulating its translocation to the lysosomal membrane where it forms a 
super-complex involving several lysosomal resident proteins and where it can encounter 
its activator Rheb. The physical interaction between lysosome and mTORC1 suggests a 
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mechanistic co-regulation, indeed several studies have demonstrated that the 
translocation and mTORC1 activation require functional lysosomes[73][25]. Here we 
found that, in contrast to this well-accepted concept, in LSD chondrocytes inhibition of 
lysosomal activity potently activated mTORC1 signaling. Others have obtained similar 
results recently[64]: in 2015, Newton et al. found that the inhibition of v-ATPase proton 
pump by Bafylomycin A1 treatment enhanced mTORC1 in chondrocytes. Their data 
point to an autophagy-independent mechanism and the authors do not provide sufficient 
explanation to this phenomenon. It is believed that in some terminally differentiated cell 
types the mechanism of lysosome-dependent mTORC1 activation might be different. 
Strikingly, our work shows that the mTORC1 over-activation can be blunted by 
pharmacological inhibition of the proteasome. Since we cannot extend our findings to 
other LSD cellular models, such as fibroblast or HeLa cell line knockout for a 
lysosomal gene, we hypothesized that lysosomal storage triggers a chondrocyte-specific 
response that enhances mTORC1 signaling.  
A cross talk between lysosomes and proteasomes, the two main degradative station of 
the cell, exists. Thus, the autophagy and UPS are two cornerstones of cellular 
catabolism that are involved in most aspects of normal physiology and development, 
and are also implicated in a broad array of pathological states. Their critical role in the 
maintenance of cellular homeostasis, suggests that their activities need to be carefully 
orchestrated. Furthermore, the amino acids derived from proteasome-mediated 
proteolysis can induce mTORC1 signaling[58], [74]. Recently, a new mechanism has 
been described by which through the involvement of the proteasome, mTORC1 exerts a 
coordinated regulation of protein synthesis and degradation.  Indeed, as well as 
increasing protein synthesis, mTORC1 activation also promotes an increased capacity 
for protein degradation.  Cells with activated mTORC1 exhibit elevated levels of intact 
and active proteasomes through a global increase in the expression of genes encoding 
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proteasome subunits. Thus, in addition to serving as a quality control mechanism for 
newly translated proteins, the enhanced proteasome activity upon mTORC1 activation 
could serve to maintain adequate pools of amino acids to sustain new protein synthesis. 
In our cellular model (Figure 45), the phenotype we described seems to be the 
consequence of an enhanced proteasome activity that, by increasing cellular amino acid 
levels, sustains mTORC1 signaling. The mechanism by which lysosome inhibition led 
to the increased proteasome activity is currently unclear. Recent data indicated that 
proteasome turnover is mediated by lysosome[66], [75]. One possibility could be that 
lysosome dysfunction by impairing proteasome turnover raises its intracellular level and 
in turn enhances its total activity. Our observations suggest the existence of additional, 
still uncharacterized, pathway through which the lysosome may indirectly regulate 
mTORC1 signaling in chondrocytes. The fine-tuning of the lysosome-proteasome cross 
talk may be of fundamental importance for chondrocytes and can be explained as an 
environmental adaptation that permits them to survive in the restricted vascular supply 
of cartilage. Similar findings have recently been reported to occur in denervated muscle 
fibers, suggesting that proteasome can sustain mTORC1 signaling during pathological 
conditions[76].  
Surprisingly, we found that an enhanced mTORC1 signaling does not significantly 
impact AVs biogenesis but rather inhibits autophagy flux at level of autophagosome-
lysosome fusion. Similarly, neurons in which mTORC1 is chronically active due to the 
lack of tuberous sclerosis complex activity showed inhibition of autophagy at the level 
of autophagosome-lysosome fusion[77]. These observations suggest that the activation 
of mTORC1 above physiological levels does not inhibit autophagy by further 
suppressing AV biogenesis, but rather acting on maturation steps. 
Consistent with previous observations, we found that mTORC1 can inhibit 
autophagosome-lysosome fusion through the modulation of UVRAG activity[17]. In 
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particular, we found that in MPS chondrocytes the hyper-phosphorylation of UVRAG 
strengthens its association with the inhibitory partner Rubicon, while having no effect 
on the interaction with members of the HOPS tethering complex. Our data suggest that 
at least in chondrocytes UVRAG modulates autophagosome-lysosome fusion as part of 
the Beclin1/Vps34 complex, further reinforcing the observation that the production of 
PI3P by Vps34 complexes regulates autophagy at multiple levels[10] (Figure 45). 
 
 
 
Figure 45. Model proposed for enhanced mTORC1 signaling in LSD chondrocytes. 
In wild-type chondrocytes (upper green part) an equilibrium exists between the intracellular 
pool of amino acids (A.A.) produced by lysosomal (Lys) and proteasomal (P) activities. This 
source of energy activates mTORC1 to physiological levels required for different activities 
within the growth plate. The fine-tuned mTORC1 activity is particularly important for 
autophagy regulation, autophagosome (AV) biogenesis, AV-Lys fusion and, in turn, 
procollagen2 (PC2) homeostasis. Lysosomal impairment in case of LSD (lower red part) creates 
an imbalance between the two catalytic organelles (Lys and P). In particular, proteasome 
amount and/or activity are enhanced, leading to an excess of intracellular A.A. responsible for 
abnormal mTORC1 signaling. Among the autophagy targets of mTORC1, UVRAG activity is 
particular sensitive to mTORC1 phosphorylation. Thus in case of LSD a stable complex 
between UVRAG and Rubicon is found; this affects primarily AV-Lys fusion leading to AV 
accumulation and subsequent delay in procollagen trafficking.  
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In the second part of my PhD thesis, I extended the findings obtained in vitro trying to 
propose the underlying mechanism for bone growth retardation in mouse models of 
LSDs.  
As expected, a block of autophagy and an upregulation of mTORC1 signaling were 
found in femoral growth plates derived from MPS VII mice. Moreover, these mice 
show severe long bone retardation when compared to control mice up to 1 month of 
age. 
The work done by our lab in the last year showed that a sustained inhibition of 
autophagy might impair bone growth at least in part by affecting type II collagen 
trafficking and secretion[30]. Accordingly, we found a significant reduction in the 
amount of collagen within the growth plate of MPS VII mice. In particular, we found a 
reduction in type X collagen and in turn an impairment of hypertrophic zone thickness, 
main marker of healthy bone growth.  
Consistent with the model we investigated in vitro, we show that genetic limitation of 
mTORC1 signaling (Gusb-/-;Rpt+/-) improved collagen levels in the cartilages and in 
turn bone growth retardation in MPS VII mice followed up to 1 month of age. This 
rescue clearly demonstrate that through the block of autophagy flux, mTORC1 exerts a 
tight regulation within the growth plate, extending the significance of the autophagic 
process in terms of the functional demands of the skeleton in growth and homeostasis. 
Moreover, we were able to show that enhancing autophagy by daily injections of Tat-
Beclin-1 peptide improved collagen levels in the cartilages and in turn bone growth 
retardation in two different mouse models of MPSs (MPS VII and MPS VI).  
This rescue occurred even without reverting lysosomal phenotype in chondrocytes, 
suggesting that targeting secondary pathways, which are altered as consequence of 
lysosomal storage, may represent an appealing therapeutic approach for the treatment of 
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MPS disease features that are currently unresponsive to therapy, such as bone growth 
retardation.  
In conclusion our data indicate a role for autophagy and mTORC1 in the genetic 
disorders affecting the skeleton, hence extending the list of diseases that can benefit 
from development of therapeutic agents targeting these two pathways.  
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